Trial Outcomes & Findings for Study of Safety, Pharmacokinetics, and Antitumor Activity of BGB-3245 in Participants With Advanced or Refractory Tumors (NCT NCT04249843)
NCT ID: NCT04249843
Last Updated: 2026-08-31
Results Overview
SAEs were defined as adverse events that resulted in death, were life-threatening, required or prolonged hospitalization, caused significant disability, or were considered important medical events.
Recruitment status
TERMINATED
Study phase
PHASE1
Target enrollment
109 participants
Primary outcome timeframe
From first dose up to 30 days after the last dose of study treatment. Maximum treatment duration was 47 months.
Results posted on
2026-08-31
Participant Flow
Participants were enrolled at 9 study sites in the United States and Australia. The study consisted of a dose escalation part (Phase 1a) and a dose expansion part (Phase 1b). The Phase 1b part of the study closed early, before all planned participants were enrolled."
Participants in Phase 1a were enrolled sequentially in cohorts of increasing doses of brimarafenib. In Phase 1b, participants in Group 1 who enrolled under Protocol Amendment 6 or 7 (from 17 Apr 2023) were randomized equally to receive 25 mg or 40 mg brimarafenib; participants enrolled prior to Protocol Amendment 6 were assigned to receive 40 mg brimarafenib in a non-randomized fashion. In Phase 1b Group 2, participants were assigned to receive 40 mg brimarafenib.
Participant milestones
| Measure |
Phase 1a: Brimarafenib 5 mg
Participants received brimarafenib 5 mg orally on Day 1 and then daily from Day 4 onwards. Participants continued treatment until disease progression, unacceptable toxicity, or study completion.
|
Phase 1a: Brimarafenib 10 mg
Participants received brimarafenib 10 mg orally on Day 1 and then daily from Day 4 onwards. Participants continued treatment until disease progression, unacceptable toxicity, or study completion.
|
Phase 1a: Brimarafenib 15 mg
Participants received brimarafenib 15 mg orally on Day 1 and then daily from Day 4 onwards. Participants continued treatment until disease progression, unacceptable toxicity, or study completion.
|
Phase 1a: Brimarafenib 25 mg
Participants received brimarafenib 25 mg orally on Day 1 and then daily from Day 4 onwards. Participants continued treatment until disease progression, unacceptable toxicity, or study completion.
|
Phase 1a: Brimarafenib 40 mg
Participants received brimarafenib 40 mg orally on Day 1 and then daily from Day 4 onwards. Participants continued treatment until disease progression, unacceptable toxicity, or study completion.
|
Phase 1a: Brimarafenib 60 mg
Participants received brimarafenib 60 mg orally on Day 1 and then daily from Day 4 onwards. Participants continued treatment until disease progression, unacceptable toxicity, or study completion.
|
Phase 1b: Group 1 (Brimarafenib 25 mg)
Participants with solid tumors harboring BRAF V600 mutations (excluding colorectal cancer \[CRC\]) who had progressed on prior BRAF and/or MEK (mitogen-activated protein kinase) inhibition were randomized using Interactive Response Technology (IRT) to receive 25 mg of brimarafenib once daily. Participants continued treatment until disease progression, unacceptable toxicity, or study completion.
|
Phase 1b: Group 1 (Brimarafenib 40 mg Randomized)
Participants with solid tumors harboring BRAF V600 mutations (excluding CRC) who had progressed on prior BRAF and/or MEK inhibition were randomized using IRT to receive 40 mg of brimarafenib once daily. Participants continued treatment until disease progression, unacceptable toxicity, or study completion.
|
Phase 1b: Group 1 (Brimarafenib 40 mg Non-Randomized)
Participants with solid tumors harboring BRAF V600 mutations (excluding CRC) enrolled under Protocol Version 4.0 were treated with 40 mg of brimarafenib once daily without randomization. Participants continued treatment until disease progression, unacceptable toxicity, or study completion.
|
Phase 1b: Group 2 (Brimarafenib 40 mg)
Participants with advanced solid tumors harboring BRAF Class II mutations or a BRAF fusion mutation were treated with 40 mg of brimarafenib once daily. Participants continued treatment until disease progression, unacceptable toxicity, or study completion.
|
|---|---|---|---|---|---|---|---|---|---|---|
|
Overall Study
STARTED
|
4
|
12
|
7
|
7
|
8
|
4
|
13
|
14
|
6
|
34
|
|
Overall Study
COMPLETED
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
Overall Study
NOT COMPLETED
|
4
|
12
|
7
|
7
|
8
|
4
|
13
|
14
|
6
|
34
|
Reasons for withdrawal
| Measure |
Phase 1a: Brimarafenib 5 mg
Participants received brimarafenib 5 mg orally on Day 1 and then daily from Day 4 onwards. Participants continued treatment until disease progression, unacceptable toxicity, or study completion.
|
Phase 1a: Brimarafenib 10 mg
Participants received brimarafenib 10 mg orally on Day 1 and then daily from Day 4 onwards. Participants continued treatment until disease progression, unacceptable toxicity, or study completion.
|
Phase 1a: Brimarafenib 15 mg
Participants received brimarafenib 15 mg orally on Day 1 and then daily from Day 4 onwards. Participants continued treatment until disease progression, unacceptable toxicity, or study completion.
|
Phase 1a: Brimarafenib 25 mg
Participants received brimarafenib 25 mg orally on Day 1 and then daily from Day 4 onwards. Participants continued treatment until disease progression, unacceptable toxicity, or study completion.
|
Phase 1a: Brimarafenib 40 mg
Participants received brimarafenib 40 mg orally on Day 1 and then daily from Day 4 onwards. Participants continued treatment until disease progression, unacceptable toxicity, or study completion.
|
Phase 1a: Brimarafenib 60 mg
Participants received brimarafenib 60 mg orally on Day 1 and then daily from Day 4 onwards. Participants continued treatment until disease progression, unacceptable toxicity, or study completion.
|
Phase 1b: Group 1 (Brimarafenib 25 mg)
Participants with solid tumors harboring BRAF V600 mutations (excluding colorectal cancer \[CRC\]) who had progressed on prior BRAF and/or MEK (mitogen-activated protein kinase) inhibition were randomized using Interactive Response Technology (IRT) to receive 25 mg of brimarafenib once daily. Participants continued treatment until disease progression, unacceptable toxicity, or study completion.
|
Phase 1b: Group 1 (Brimarafenib 40 mg Randomized)
Participants with solid tumors harboring BRAF V600 mutations (excluding CRC) who had progressed on prior BRAF and/or MEK inhibition were randomized using IRT to receive 40 mg of brimarafenib once daily. Participants continued treatment until disease progression, unacceptable toxicity, or study completion.
|
Phase 1b: Group 1 (Brimarafenib 40 mg Non-Randomized)
Participants with solid tumors harboring BRAF V600 mutations (excluding CRC) enrolled under Protocol Version 4.0 were treated with 40 mg of brimarafenib once daily without randomization. Participants continued treatment until disease progression, unacceptable toxicity, or study completion.
|
Phase 1b: Group 2 (Brimarafenib 40 mg)
Participants with advanced solid tumors harboring BRAF Class II mutations or a BRAF fusion mutation were treated with 40 mg of brimarafenib once daily. Participants continued treatment until disease progression, unacceptable toxicity, or study completion.
|
|---|---|---|---|---|---|---|---|---|---|---|
|
Overall Study
Adverse Event
|
0
|
0
|
1
|
0
|
0
|
2
|
1
|
1
|
0
|
1
|
|
Overall Study
Withdrawal by Subject
|
0
|
3
|
2
|
4
|
3
|
0
|
2
|
1
|
4
|
4
|
|
Overall Study
Death
|
2
|
5
|
2
|
2
|
3
|
2
|
3
|
5
|
1
|
18
|
|
Overall Study
Lost to Follow-up
|
0
|
1
|
0
|
0
|
1
|
0
|
0
|
0
|
1
|
3
|
|
Overall Study
Physician Decision
|
0
|
1
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
Overall Study
Progressive Disease
|
2
|
2
|
2
|
1
|
1
|
0
|
0
|
0
|
0
|
1
|
|
Overall Study
Sponsor Decision
|
0
|
0
|
0
|
0
|
0
|
0
|
7
|
7
|
0
|
7
|
Baseline Characteristics
Study of Safety, Pharmacokinetics, and Antitumor Activity of BGB-3245 in Participants With Advanced or Refractory Tumors
Baseline characteristics by cohort
| Measure |
Phase 1a: Brimarafenib 5 mg
n=4 Participants
Participants received brimarafenib 5 mg orally on Day 1 and then daily from Day 4 onwards. Participants continued treatment until disease progression, unacceptable toxicity, or study completion.
|
Phase 1a: Brimarafenib 10 mg
n=12 Participants
Participants received brimarafenib 10 mg orally on Day 1 and then daily from Day 4 onwards. Participants continued treatment until disease progression, unacceptable toxicity, or study completion.
|
Phase 1a: Brimarafenib 15 mg
n=7 Participants
Participants received brimarafenib 15 mg orally on Day 1 and then daily from Day 4 onwards. Participants continued treatment until disease progression, unacceptable toxicity, or study completion.
|
Phase 1a: Brimarafenib 25 mg
n=7 Participants
Participants received brimarafenib 25 mg orally on Day 1 and then daily from Day 4 onwards. Participants continued treatment until disease progression, unacceptable toxicity, or study completion.
|
Phase 1a: Brimarafenib 40 mg
n=8 Participants
Participants received brimarafenib 40 mg orally on Day 1 and then daily from Day 4 onwards. Participants continued treatment until disease progression, unacceptable toxicity, or study completion.
|
Phase 1a: Brimarafenib 60 mg
n=4 Participants
Participants received brimarafenib 60 mg orally on Day 1 and then daily from Day 4 onwards. Participants continued treatment until disease progression, unacceptable toxicity, or study completion.
|
Phase 1b: Group 1 (Brimarafenib 25 mg)
n=13 Participants
Participants with solid tumors harboring BRAF V600 mutations (excluding colorectal cancer \[CRC\]) who had progressed on prior BRAF and/or MEK (mitogen-activated protein kinase) inhibition were randomized using Interactive Response Technology (IRT) to receive 25 mg of brimarafenib once daily. Participants continued treatment until disease progression, unacceptable toxicity, or study completion.
|
Phase 1b: Group 1 (Brimarafenib 40 mg Randomized)
n=14 Participants
Participants with solid tumors harboring BRAF V600 mutations (excluding CRC) who had progressed on prior BRAF and/or MEK inhibition were randomized using IRT to receive 40 mg of BGB-3245 once daily.
|
Phase 1b: Group 1 (Brimarafenib 40 mg Non-Randomized)
n=6 Participants
Participants with solid tumors harboring BRAF V600 mutations (excluding CRC) enrolled under Protocol Version 4.0 were treated with 40 mg of brimarafenib once daily without randomization. Participants continued treatment until disease progression, unacceptable toxicity, or study completion.
|
Phase 1b: Group 2 (Brimarafenib 40 mg)
n=34 Participants
Participants with advanced solid tumors harboring BRAF Class II mutations or a BRAF fusion mutation were treated with 40 mg of brimarafenib once daily. Participants continued treatment until disease progression, unacceptable toxicity, or study completion.
|
Total
n=109 Participants
Total of all reporting groups
|
|---|---|---|---|---|---|---|---|---|---|---|---|
|
Age, Continuous
|
65.8 years
STANDARD_DEVIATION 12.9 • n=14 Participants
|
51.8 years
STANDARD_DEVIATION 16.3 • n=36 Participants
|
57.7 years
STANDARD_DEVIATION 10.1 • n=324 Participants
|
65.6 years
STANDARD_DEVIATION 10.0 • n=49 Participants
|
59.0 years
STANDARD_DEVIATION 11.8 • n=573 Participants
|
65.0 years
STANDARD_DEVIATION 10.3 • n=9 Participants
|
65.5 years
STANDARD_DEVIATION 8.4 • n=8 Participants
|
56.4 years
STANDARD_DEVIATION 14.7 • n=7 Participants
|
54.3 years
STANDARD_DEVIATION 6.6 • n=18 Participants
|
58.2 years
STANDARD_DEVIATION 15.4 • n=19 Participants
|
58.9 years
STANDARD_DEVIATION 13.5 • n=31 Participants
|
|
Sex: Female, Male
Female
|
2 Participants
n=14 Participants
|
6 Participants
n=36 Participants
|
4 Participants
n=324 Participants
|
2 Participants
n=49 Participants
|
3 Participants
n=573 Participants
|
2 Participants
n=9 Participants
|
7 Participants
n=8 Participants
|
6 Participants
n=7 Participants
|
4 Participants
n=18 Participants
|
20 Participants
n=19 Participants
|
56 Participants
n=31 Participants
|
|
Sex: Female, Male
Male
|
2 Participants
n=14 Participants
|
6 Participants
n=36 Participants
|
3 Participants
n=324 Participants
|
5 Participants
n=49 Participants
|
5 Participants
n=573 Participants
|
2 Participants
n=9 Participants
|
6 Participants
n=8 Participants
|
8 Participants
n=7 Participants
|
2 Participants
n=18 Participants
|
14 Participants
n=19 Participants
|
53 Participants
n=31 Participants
|
|
Ethnicity (NIH/OMB)
Hispanic or Latino
|
1 Participants
n=14 Participants
|
0 Participants
n=36 Participants
|
0 Participants
n=324 Participants
|
0 Participants
n=49 Participants
|
0 Participants
n=573 Participants
|
1 Participants
n=9 Participants
|
3 Participants
n=8 Participants
|
1 Participants
n=7 Participants
|
1 Participants
n=18 Participants
|
1 Participants
n=19 Participants
|
8 Participants
n=31 Participants
|
|
Ethnicity (NIH/OMB)
Not Hispanic or Latino
|
3 Participants
n=14 Participants
|
11 Participants
n=36 Participants
|
6 Participants
n=324 Participants
|
7 Participants
n=49 Participants
|
6 Participants
n=573 Participants
|
3 Participants
n=9 Participants
|
10 Participants
n=8 Participants
|
12 Participants
n=7 Participants
|
4 Participants
n=18 Participants
|
32 Participants
n=19 Participants
|
94 Participants
n=31 Participants
|
|
Ethnicity (NIH/OMB)
Unknown or Not Reported
|
0 Participants
n=14 Participants
|
1 Participants
n=36 Participants
|
1 Participants
n=324 Participants
|
0 Participants
n=49 Participants
|
2 Participants
n=573 Participants
|
0 Participants
n=9 Participants
|
0 Participants
n=8 Participants
|
1 Participants
n=7 Participants
|
1 Participants
n=18 Participants
|
1 Participants
n=19 Participants
|
7 Participants
n=31 Participants
|
|
Race/Ethnicity, Customized
American Indian or Alaska Native
|
0 Participants
n=14 Participants
|
0 Participants
n=36 Participants
|
0 Participants
n=324 Participants
|
0 Participants
n=49 Participants
|
0 Participants
n=573 Participants
|
0 Participants
n=9 Participants
|
0 Participants
n=8 Participants
|
0 Participants
n=7 Participants
|
0 Participants
n=18 Participants
|
0 Participants
n=19 Participants
|
0 Participants
n=31 Participants
|
|
Race/Ethnicity, Customized
Asian
|
0 Participants
n=14 Participants
|
0 Participants
n=36 Participants
|
0 Participants
n=324 Participants
|
1 Participants
n=49 Participants
|
0 Participants
n=573 Participants
|
0 Participants
n=9 Participants
|
1 Participants
n=8 Participants
|
1 Participants
n=7 Participants
|
0 Participants
n=18 Participants
|
2 Participants
n=19 Participants
|
5 Participants
n=31 Participants
|
|
Race/Ethnicity, Customized
Black or African American
|
0 Participants
n=14 Participants
|
0 Participants
n=36 Participants
|
0 Participants
n=324 Participants
|
0 Participants
n=49 Participants
|
0 Participants
n=573 Participants
|
0 Participants
n=9 Participants
|
0 Participants
n=8 Participants
|
0 Participants
n=7 Participants
|
0 Participants
n=18 Participants
|
1 Participants
n=19 Participants
|
1 Participants
n=31 Participants
|
|
Race/Ethnicity, Customized
Native Hawaiian or other Pacific Islander
|
0 Participants
n=14 Participants
|
0 Participants
n=36 Participants
|
0 Participants
n=324 Participants
|
0 Participants
n=49 Participants
|
0 Participants
n=573 Participants
|
0 Participants
n=9 Participants
|
0 Participants
n=8 Participants
|
0 Participants
n=7 Participants
|
0 Participants
n=18 Participants
|
0 Participants
n=19 Participants
|
0 Participants
n=31 Participants
|
|
Race/Ethnicity, Customized
White
|
4 Participants
n=14 Participants
|
10 Participants
n=36 Participants
|
6 Participants
n=324 Participants
|
6 Participants
n=49 Participants
|
7 Participants
n=573 Participants
|
3 Participants
n=9 Participants
|
11 Participants
n=8 Participants
|
12 Participants
n=7 Participants
|
5 Participants
n=18 Participants
|
26 Participants
n=19 Participants
|
90 Participants
n=31 Participants
|
|
Race/Ethnicity, Customized
Multiple
|
0 Participants
n=14 Participants
|
1 Participants
n=36 Participants
|
0 Participants
n=324 Participants
|
0 Participants
n=49 Participants
|
0 Participants
n=573 Participants
|
0 Participants
n=9 Participants
|
0 Participants
n=8 Participants
|
0 Participants
n=7 Participants
|
0 Participants
n=18 Participants
|
0 Participants
n=19 Participants
|
1 Participants
n=31 Participants
|
|
Race/Ethnicity, Customized
Not Reported/Unknown
|
0 Participants
n=14 Participants
|
1 Participants
n=36 Participants
|
1 Participants
n=324 Participants
|
0 Participants
n=49 Participants
|
1 Participants
n=573 Participants
|
1 Participants
n=9 Participants
|
0 Participants
n=8 Participants
|
1 Participants
n=7 Participants
|
1 Participants
n=18 Participants
|
5 Participants
n=19 Participants
|
11 Participants
n=31 Participants
|
|
Race/Ethnicity, Customized
Missing
|
0 Participants
n=14 Participants
|
0 Participants
n=36 Participants
|
0 Participants
n=324 Participants
|
0 Participants
n=49 Participants
|
0 Participants
n=573 Participants
|
0 Participants
n=9 Participants
|
1 Participants
n=8 Participants
|
0 Participants
n=7 Participants
|
0 Participants
n=18 Participants
|
0 Participants
n=19 Participants
|
1 Participants
n=31 Participants
|
|
Region of Enrollment
United States
|
0 participants
n=14 Participants
|
6 participants
n=36 Participants
|
5 participants
n=324 Participants
|
5 participants
n=49 Participants
|
5 participants
n=573 Participants
|
3 participants
n=9 Participants
|
10 participants
n=8 Participants
|
8 participants
n=7 Participants
|
6 participants
n=18 Participants
|
20 participants
n=19 Participants
|
68 participants
n=31 Participants
|
|
Region of Enrollment
Australia
|
4 participants
n=14 Participants
|
6 participants
n=36 Participants
|
2 participants
n=324 Participants
|
2 participants
n=49 Participants
|
3 participants
n=573 Participants
|
1 participants
n=9 Participants
|
3 participants
n=8 Participants
|
6 participants
n=7 Participants
|
0 participants
n=18 Participants
|
14 participants
n=19 Participants
|
41 participants
n=31 Participants
|
|
The Eastern Cooperative Oncology Group (ECOG) Performance Status
0 (fully Active)
|
2 Participants
n=14 Participants
|
7 Participants
n=36 Participants
|
3 Participants
n=324 Participants
|
5 Participants
n=49 Participants
|
3 Participants
n=573 Participants
|
3 Participants
n=9 Participants
|
7 Participants
n=8 Participants
|
8 Participants
n=7 Participants
|
1 Participants
n=18 Participants
|
14 Participants
n=19 Participants
|
53 Participants
n=31 Participants
|
|
The Eastern Cooperative Oncology Group (ECOG) Performance Status
1 (Limited strenuous activity; light work possible)
|
1 Participants
n=14 Participants
|
5 Participants
n=36 Participants
|
4 Participants
n=324 Participants
|
2 Participants
n=49 Participants
|
5 Participants
n=573 Participants
|
1 Participants
n=9 Participants
|
6 Participants
n=8 Participants
|
5 Participants
n=7 Participants
|
4 Participants
n=18 Participants
|
18 Participants
n=19 Participants
|
51 Participants
n=31 Participants
|
|
The Eastern Cooperative Oncology Group (ECOG) Performance Status
Missing
|
1 Participants
n=14 Participants
|
0 Participants
n=36 Participants
|
0 Participants
n=324 Participants
|
0 Participants
n=49 Participants
|
0 Participants
n=573 Participants
|
0 Participants
n=9 Participants
|
0 Participants
n=8 Participants
|
1 Participants
n=7 Participants
|
1 Participants
n=18 Participants
|
2 Participants
n=19 Participants
|
5 Participants
n=31 Participants
|
PRIMARY outcome
Timeframe: From first dose up to 30 days after the last dose of study treatment. Maximum treatment duration was 47 months.Population: Safety Population
SAEs were defined as adverse events that resulted in death, were life-threatening, required or prolonged hospitalization, caused significant disability, or were considered important medical events.
Outcome measures
| Measure |
Phase 1a: Brimarafenib 60 mg
n=4 Participants
Participants received brimarafenib 60 mg orally on Day 1 and then daily from Day 4 onwards. Participants continued treatment until disease progression, unacceptable toxicity, or study completion.
|
Phase 1b: Group 1 (Brimarafenib 40 mg Non-Randomized)
Participants with solid tumors harboring BRAF V600 mutations (excluding CRC) enrolled under Protocol Version 4.0 were treated with 40 mg of brimarafenib once daily without randomization. Participants continued treatment until disease progression, unacceptable toxicity, or study completion.
|
Phase 1b: Group 2 (Brimarafenib 40 mg)
Participants with advanced solid tumors harboring BRAF Class II mutations or a BRAF fusion mutation were treated with 40 mg of brimarafenib once daily.
|
Phase 1a: Brimarafenib 40 mg
n=8 Participants
Participants received brimarafenib 40 mg orally on Day 1 and then daily from Day 4 onwards. Participants continued treatment until disease progression, unacceptable toxicity, or study completion.
|
Phase 1a: Brimarafenib 5 mg
n=4 Participants
Participants received brimarafenib 5 mg orally on Day 1 and then daily from Day 4 onwards. Participants continued treatment until disease progression, unacceptable toxicity, or study completion.
|
Phase 1a: Brimarafenib 10 mg
n=12 Participants
Participants received brimarafenib 10 mg orally on Day 1 and then daily from Day 4 onwards. Participants continued treatment until disease progression, unacceptable toxicity, or study completion.
|
Phase 1a: Brimarafenib 15 mg
n=7 Participants
Participants received brimarafenib 15 mg orally on Day 1 and then daily from Day 4 onwards. Participants continued treatment until disease progression, unacceptable toxicity, or study completion.
|
Phase 1a: Brimarafenib 25 mg
n=7 Participants
Participants received brimarafenib 25 mg orally on Day 1 and then daily from Day 4 onwards. Participants continued treatment until disease progression, unacceptable toxicity, or study completion.
|
Phase 1b: Group 1 (25 mg)
Participants with solid tumors harboring BRAF V600 mutations (excluding colorectal cancer \[CRC\]) who had progressed on prior BRAF and/or MEK (mitogen-activated protein kinase kinase) inhibition were randomized using Interactive Response Technology (IRT) to receive 25 mg of BGB-3245 once daily.
|
Phase 1b: Group 1 (40 mg Randomized)
Participants with solid tumors harboring BRAF V600 mutations (excluding CRC) who had progressed on prior BRAF and/or MEK inhibition were randomized using IRT to receive 40 mg of BGB-3245 once daily.
|
|---|---|---|---|---|---|---|---|---|---|---|
|
Phase 1a: Number of Participants Experiencing Treatment-Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)
At least one TEAE
|
4 Participants
|
—
|
—
|
8 Participants
|
4 Participants
|
12 Participants
|
7 Participants
|
7 Participants
|
—
|
—
|
|
Phase 1a: Number of Participants Experiencing Treatment-Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)
At least one SAE
|
4 Participants
|
—
|
—
|
5 Participants
|
2 Participants
|
8 Participants
|
5 Participants
|
3 Participants
|
—
|
—
|
PRIMARY outcome
Timeframe: From first dose through the end of Cycle 1 (approximately 30 days)Population: Safety Analysis Set
The MTD was determined by the Safety Monitoring Committee (SMC) based on the occurrence of dose-limiting toxicities (DLTs), overall safety, and tolerability. The MTD reflects the dose associated with an acceptable level of toxicity (30%).
Outcome measures
| Measure |
Phase 1a: Brimarafenib 60 mg
Participants received brimarafenib 60 mg orally on Day 1 and then daily from Day 4 onwards. Participants continued treatment until disease progression, unacceptable toxicity, or study completion.
|
Phase 1b: Group 1 (Brimarafenib 40 mg Non-Randomized)
Participants with solid tumors harboring BRAF V600 mutations (excluding CRC) enrolled under Protocol Version 4.0 were treated with 40 mg of brimarafenib once daily without randomization. Participants continued treatment until disease progression, unacceptable toxicity, or study completion.
|
Phase 1b: Group 2 (Brimarafenib 40 mg)
Participants with advanced solid tumors harboring BRAF Class II mutations or a BRAF fusion mutation were treated with 40 mg of brimarafenib once daily.
|
Phase 1a: Brimarafenib 40 mg
Participants received brimarafenib 40 mg orally on Day 1 and then daily from Day 4 onwards. Participants continued treatment until disease progression, unacceptable toxicity, or study completion.
|
Phase 1a: Brimarafenib 5 mg
n=42 Participants
Participants received brimarafenib 5 mg orally on Day 1 and then daily from Day 4 onwards. Participants continued treatment until disease progression, unacceptable toxicity, or study completion.
|
Phase 1a: Brimarafenib 10 mg
Participants received brimarafenib 10 mg orally on Day 1 and then daily from Day 4 onwards. Participants continued treatment until disease progression, unacceptable toxicity, or study completion.
|
Phase 1a: Brimarafenib 15 mg
Participants received brimarafenib 15 mg orally on Day 1 and then daily from Day 4 onwards. Participants continued treatment until disease progression, unacceptable toxicity, or study completion.
|
Phase 1a: Brimarafenib 25 mg
Participants received brimarafenib 25 mg orally on Day 1 and then daily from Day 4 onwards. Participants continued treatment until disease progression, unacceptable toxicity, or study completion.
|
Phase 1b: Group 1 (25 mg)
Participants with solid tumors harboring BRAF V600 mutations (excluding colorectal cancer \[CRC\]) who had progressed on prior BRAF and/or MEK (mitogen-activated protein kinase kinase) inhibition were randomized using Interactive Response Technology (IRT) to receive 25 mg of BGB-3245 once daily.
|
Phase 1b: Group 1 (40 mg Randomized)
Participants with solid tumors harboring BRAF V600 mutations (excluding CRC) who had progressed on prior BRAF and/or MEK inhibition were randomized using IRT to receive 40 mg of BGB-3245 once daily.
|
|---|---|---|---|---|---|---|---|---|---|---|
|
Phase 1a: Maximum Tolerated Dose (MTD) of Brimarafenib
|
—
|
—
|
—
|
—
|
40 milligrams (mg) once a day (QD)
|
—
|
—
|
—
|
—
|
—
|
PRIMARY outcome
Timeframe: From first dose of study drug through last dose (maximum treatment duration in Phase 1b was 25 months)Population: Phase 1b Safety Population
The optimal RP2D was to be determined based on safety, tolerability, efficacy, and pharmacokinetic (PK) data obtained from participants treated with the two dose levels tested in Phase 1b (25 mg and 40 mg). The RP2D could not be determined since the study was terminated early.
Outcome measures
| Measure |
Phase 1a: Brimarafenib 60 mg
Participants received brimarafenib 60 mg orally on Day 1 and then daily from Day 4 onwards. Participants continued treatment until disease progression, unacceptable toxicity, or study completion.
|
Phase 1b: Group 1 (Brimarafenib 40 mg Non-Randomized)
Participants with solid tumors harboring BRAF V600 mutations (excluding CRC) enrolled under Protocol Version 4.0 were treated with 40 mg of brimarafenib once daily without randomization. Participants continued treatment until disease progression, unacceptable toxicity, or study completion.
|
Phase 1b: Group 2 (Brimarafenib 40 mg)
Participants with advanced solid tumors harboring BRAF Class II mutations or a BRAF fusion mutation were treated with 40 mg of brimarafenib once daily.
|
Phase 1a: Brimarafenib 40 mg
Participants received brimarafenib 40 mg orally on Day 1 and then daily from Day 4 onwards. Participants continued treatment until disease progression, unacceptable toxicity, or study completion.
|
Phase 1a: Brimarafenib 5 mg
n=67 Participants
Participants received brimarafenib 5 mg orally on Day 1 and then daily from Day 4 onwards. Participants continued treatment until disease progression, unacceptable toxicity, or study completion.
|
Phase 1a: Brimarafenib 10 mg
Participants received brimarafenib 10 mg orally on Day 1 and then daily from Day 4 onwards. Participants continued treatment until disease progression, unacceptable toxicity, or study completion.
|
Phase 1a: Brimarafenib 15 mg
Participants received brimarafenib 15 mg orally on Day 1 and then daily from Day 4 onwards. Participants continued treatment until disease progression, unacceptable toxicity, or study completion.
|
Phase 1a: Brimarafenib 25 mg
Participants received brimarafenib 25 mg orally on Day 1 and then daily from Day 4 onwards. Participants continued treatment until disease progression, unacceptable toxicity, or study completion.
|
Phase 1b: Group 1 (25 mg)
Participants with solid tumors harboring BRAF V600 mutations (excluding colorectal cancer \[CRC\]) who had progressed on prior BRAF and/or MEK (mitogen-activated protein kinase kinase) inhibition were randomized using Interactive Response Technology (IRT) to receive 25 mg of BGB-3245 once daily.
|
Phase 1b: Group 1 (40 mg Randomized)
Participants with solid tumors harboring BRAF V600 mutations (excluding CRC) who had progressed on prior BRAF and/or MEK inhibition were randomized using IRT to receive 40 mg of BGB-3245 once daily.
|
|---|---|---|---|---|---|---|---|---|---|---|
|
Phase 1b: Recommended Phase 2 Dose (RP2D) Confirmation
|
—
|
—
|
—
|
—
|
NA mg
The study was terminated before all planned participants in Phase 1b part were enrolled and the optimal RP2D could not be established based on the data that were collected.
|
—
|
—
|
—
|
—
|
—
|
PRIMARY outcome
Timeframe: From first dose until disease progression or death, Maximum treatment duration was 25 months.Population: The Efficacy Evaluable Population included all dosed participants who had radiologically confirmed evaluable disease at baseline and at least 1 evaluable postbaseline radiological tumor response assessment.
ORR was defined as the percentage of participants who achieved a best overall response of complete response (CR) or partial response (PR) per Response Evaluation Criteria in Solid Tumors (RECIST v1.1)
Outcome measures
| Measure |
Phase 1a: Brimarafenib 60 mg
Participants received brimarafenib 60 mg orally on Day 1 and then daily from Day 4 onwards. Participants continued treatment until disease progression, unacceptable toxicity, or study completion.
|
Phase 1b: Group 1 (Brimarafenib 40 mg Non-Randomized)
Participants with solid tumors harboring BRAF V600 mutations (excluding CRC) enrolled under Protocol Version 4.0 were treated with 40 mg of brimarafenib once daily without randomization. Participants continued treatment until disease progression, unacceptable toxicity, or study completion.
|
Phase 1b: Group 2 (Brimarafenib 40 mg)
Participants with advanced solid tumors harboring BRAF Class II mutations or a BRAF fusion mutation were treated with 40 mg of brimarafenib once daily.
|
Phase 1a: Brimarafenib 40 mg
Participants received brimarafenib 40 mg orally on Day 1 and then daily from Day 4 onwards. Participants continued treatment until disease progression, unacceptable toxicity, or study completion.
|
Phase 1a: Brimarafenib 5 mg
n=11 Participants
Participants received brimarafenib 5 mg orally on Day 1 and then daily from Day 4 onwards. Participants continued treatment until disease progression, unacceptable toxicity, or study completion.
|
Phase 1a: Brimarafenib 10 mg
n=13 Participants
Participants received brimarafenib 10 mg orally on Day 1 and then daily from Day 4 onwards. Participants continued treatment until disease progression, unacceptable toxicity, or study completion.
|
Phase 1a: Brimarafenib 15 mg
n=4 Participants
Participants received brimarafenib 15 mg orally on Day 1 and then daily from Day 4 onwards. Participants continued treatment until disease progression, unacceptable toxicity, or study completion.
|
Phase 1a: Brimarafenib 25 mg
n=26 Participants
Participants received brimarafenib 25 mg orally on Day 1 and then daily from Day 4 onwards. Participants continued treatment until disease progression, unacceptable toxicity, or study completion.
|
Phase 1b: Group 1 (25 mg)
Participants with solid tumors harboring BRAF V600 mutations (excluding colorectal cancer \[CRC\]) who had progressed on prior BRAF and/or MEK (mitogen-activated protein kinase kinase) inhibition were randomized using Interactive Response Technology (IRT) to receive 25 mg of BGB-3245 once daily.
|
Phase 1b: Group 1 (40 mg Randomized)
Participants with solid tumors harboring BRAF V600 mutations (excluding CRC) who had progressed on prior BRAF and/or MEK inhibition were randomized using IRT to receive 40 mg of BGB-3245 once daily.
|
|---|---|---|---|---|---|---|---|---|---|---|
|
Phase 1b: Objective Response Rate (ORR)
|
—
|
—
|
—
|
—
|
0 Percentage of Participants
Interval 0.0 to 28.5
|
7.7 Percentage of Participants
Interval 0.2 to 36.0
|
0 Percentage of Participants
Interval 0.0 to 60.2
|
19.2 Percentage of Participants
Interval 6.6 to 39.4
|
—
|
—
|
SECONDARY outcome
Timeframe: From first dose until disease progression or death, Maximum treatment duration was 47 months.Population: Efficacy Evaluable Population
ORR was defined as the percentage of participants who achieved a best overall response of complete response (CR) or partial response (PR) per Response Evaluation Criteria in Solid Tumors (RECIST v1.1)
Outcome measures
| Measure |
Phase 1a: Brimarafenib 60 mg
n=3 Participants
Participants received brimarafenib 60 mg orally on Day 1 and then daily from Day 4 onwards. Participants continued treatment until disease progression, unacceptable toxicity, or study completion.
|
Phase 1b: Group 1 (Brimarafenib 40 mg Non-Randomized)
Participants with solid tumors harboring BRAF V600 mutations (excluding CRC) enrolled under Protocol Version 4.0 were treated with 40 mg of brimarafenib once daily without randomization. Participants continued treatment until disease progression, unacceptable toxicity, or study completion.
|
Phase 1b: Group 2 (Brimarafenib 40 mg)
Participants with advanced solid tumors harboring BRAF Class II mutations or a BRAF fusion mutation were treated with 40 mg of brimarafenib once daily.
|
Phase 1a: Brimarafenib 40 mg
n=6 Participants
Participants received brimarafenib 40 mg orally on Day 1 and then daily from Day 4 onwards. Participants continued treatment until disease progression, unacceptable toxicity, or study completion.
|
Phase 1a: Brimarafenib 5 mg
n=2 Participants
Participants received brimarafenib 5 mg orally on Day 1 and then daily from Day 4 onwards. Participants continued treatment until disease progression, unacceptable toxicity, or study completion.
|
Phase 1a: Brimarafenib 10 mg
n=10 Participants
Participants received brimarafenib 10 mg orally on Day 1 and then daily from Day 4 onwards. Participants continued treatment until disease progression, unacceptable toxicity, or study completion.
|
Phase 1a: Brimarafenib 15 mg
n=7 Participants
Participants received brimarafenib 15 mg orally on Day 1 and then daily from Day 4 onwards. Participants continued treatment until disease progression, unacceptable toxicity, or study completion.
|
Phase 1a: Brimarafenib 25 mg
n=5 Participants
Participants received brimarafenib 25 mg orally on Day 1 and then daily from Day 4 onwards. Participants continued treatment until disease progression, unacceptable toxicity, or study completion.
|
Phase 1b: Group 1 (25 mg)
Participants with solid tumors harboring BRAF V600 mutations (excluding colorectal cancer \[CRC\]) who had progressed on prior BRAF and/or MEK (mitogen-activated protein kinase kinase) inhibition were randomized using Interactive Response Technology (IRT) to receive 25 mg of BGB-3245 once daily.
|
Phase 1b: Group 1 (40 mg Randomized)
Participants with solid tumors harboring BRAF V600 mutations (excluding CRC) who had progressed on prior BRAF and/or MEK inhibition were randomized using IRT to receive 40 mg of BGB-3245 once daily.
|
|---|---|---|---|---|---|---|---|---|---|---|
|
Phase 1a: ORR
|
66.7 Percentage of Participants
Interval 9.4 to 99.2
|
—
|
—
|
16.7 Percentage of Participants
Interval 0.4 to 64.1
|
0 Percentage of Participants
Interval 0.0 to 84.2
|
20.0 Percentage of Participants
Interval 2.5 to 55.6
|
14.3 Percentage of Participants
Interval 0.4 to 57.9
|
0.0 Percentage of Participants
Interval 0.0 to 52.0
|
—
|
—
|
SECONDARY outcome
Timeframe: From first dose until disease progression or death, Maximum treatment duration was 47 months in Phase 1a and 25 months in Phase 1b.Population: Participants in the Efficacy evaluable population with a CR or PR
DOR was defined as the time from the date that a confirmed response (CR or PR) was first observed per RECIST 1.1 to the date of first documented disease progression or death, whichever occurred first. Median DOR was estimated using the Kaplan-Meier method.
Outcome measures
| Measure |
Phase 1a: Brimarafenib 60 mg
n=2 Participants
Participants received brimarafenib 60 mg orally on Day 1 and then daily from Day 4 onwards. Participants continued treatment until disease progression, unacceptable toxicity, or study completion.
|
Phase 1b: Group 1 (Brimarafenib 40 mg Non-Randomized)
Participants with solid tumors harboring BRAF V600 mutations (excluding CRC) enrolled under Protocol Version 4.0 were treated with 40 mg of brimarafenib once daily without randomization. Participants continued treatment until disease progression, unacceptable toxicity, or study completion.
|
Phase 1b: Group 2 (Brimarafenib 40 mg)
n=5 Participants
Participants with advanced solid tumors harboring BRAF Class II mutations or a BRAF fusion mutation were treated with 40 mg of brimarafenib once daily.
|
Phase 1a: Brimarafenib 40 mg
n=1 Participants
Participants received brimarafenib 40 mg orally on Day 1 and then daily from Day 4 onwards. Participants continued treatment until disease progression, unacceptable toxicity, or study completion.
|
Phase 1a: Brimarafenib 5 mg
Participants received brimarafenib 5 mg orally on Day 1 and then daily from Day 4 onwards. Participants continued treatment until disease progression, unacceptable toxicity, or study completion.
|
Phase 1a: Brimarafenib 10 mg
n=2 Participants
Participants received brimarafenib 10 mg orally on Day 1 and then daily from Day 4 onwards. Participants continued treatment until disease progression, unacceptable toxicity, or study completion.
|
Phase 1a: Brimarafenib 15 mg
n=1 Participants
Participants received brimarafenib 15 mg orally on Day 1 and then daily from Day 4 onwards. Participants continued treatment until disease progression, unacceptable toxicity, or study completion.
|
Phase 1a: Brimarafenib 25 mg
Participants received brimarafenib 25 mg orally on Day 1 and then daily from Day 4 onwards. Participants continued treatment until disease progression, unacceptable toxicity, or study completion.
|
Phase 1b: Group 1 (25 mg)
Participants with solid tumors harboring BRAF V600 mutations (excluding colorectal cancer \[CRC\]) who had progressed on prior BRAF and/or MEK (mitogen-activated protein kinase kinase) inhibition were randomized using Interactive Response Technology (IRT) to receive 25 mg of BGB-3245 once daily.
|
Phase 1b: Group 1 (40 mg Randomized)
n=1 Participants
Participants with solid tumors harboring BRAF V600 mutations (excluding CRC) who had progressed on prior BRAF and/or MEK inhibition were randomized using IRT to receive 40 mg of BGB-3245 once daily.
|
|---|---|---|---|---|---|---|---|---|---|---|
|
Duration of Response (DOR)
|
NA Months
The study was terminated early due to lack of clinical benefit. Per the revised Statistical Analysis Plan, tabulated efficacy analyses were ORR and PFS. Duration of response was not prespecified for summary tabulation; therefore, no tabular results are available for this outcome
|
—
|
NA Months
The study was terminated early due to lack of clinical benefit. Per the revised Statistical Analysis Plan, tabulated efficacy analyses were ORR and PFS. Duration of response was not prespecified for summary tabulation; therefore, no tabular results are available for this outcome
|
NA Months
The study was terminated early due to lack of clinical benefit. Per the revised Statistical Analysis Plan, tabulated efficacy analyses were ORR and PFS. Duration of response was not prespecified for summary tabulation; therefore, no tabular results are available for this outcome
|
—
|
NA Months
The study was terminated early due to lack of clinical benefit. Per the revised Statistical Analysis Plan, tabulated efficacy analyses were ORR and PFS. Duration of response was not prespecified for summary tabulation; therefore, no tabular results are available for this outcome
|
NA Months
The study was terminated early due to lack of clinical benefit. Per the revised Statistical Analysis Plan, tabulated efficacy analyses were ORR and PFS. Duration of response was not prespecified for summary tabulation; therefore, no tabular results are available for this outcome
|
—
|
—
|
NA Months
The study was terminated early due to lack of clinical benefit. Per the revised Statistical Analysis Plan, tabulated efficacy analyses were ORR and PFS. Duration of response was not prespecified for summary tabulation; therefore, no tabular results are available for this outcome
|
SECONDARY outcome
Timeframe: From first dose until disease progression or death, Maximum treatment duration was 47 months.Population: Efficacy Evaluable Population
CBR is defined as the percentage of participants with confirmed CR, PR, or durable stable disease (stable disease ≥ 24 weeks).
Outcome measures
| Measure |
Phase 1a: Brimarafenib 60 mg
n=3 Participants
Participants received brimarafenib 60 mg orally on Day 1 and then daily from Day 4 onwards. Participants continued treatment until disease progression, unacceptable toxicity, or study completion.
|
Phase 1b: Group 1 (Brimarafenib 40 mg Non-Randomized)
n=4 Participants
Participants with solid tumors harboring BRAF V600 mutations (excluding CRC) enrolled under Protocol Version 4.0 were treated with 40 mg of brimarafenib once daily without randomization. Participants continued treatment until disease progression, unacceptable toxicity, or study completion.
|
Phase 1b: Group 2 (Brimarafenib 40 mg)
n=26 Participants
Participants with advanced solid tumors harboring BRAF Class II mutations or a BRAF fusion mutation were treated with 40 mg of brimarafenib once daily.
|
Phase 1a: Brimarafenib 40 mg
n=6 Participants
Participants received brimarafenib 40 mg orally on Day 1 and then daily from Day 4 onwards. Participants continued treatment until disease progression, unacceptable toxicity, or study completion.
|
Phase 1a: Brimarafenib 5 mg
n=2 Participants
Participants received brimarafenib 5 mg orally on Day 1 and then daily from Day 4 onwards. Participants continued treatment until disease progression, unacceptable toxicity, or study completion.
|
Phase 1a: Brimarafenib 10 mg
n=10 Participants
Participants received brimarafenib 10 mg orally on Day 1 and then daily from Day 4 onwards. Participants continued treatment until disease progression, unacceptable toxicity, or study completion.
|
Phase 1a: Brimarafenib 15 mg
n=7 Participants
Participants received brimarafenib 15 mg orally on Day 1 and then daily from Day 4 onwards. Participants continued treatment until disease progression, unacceptable toxicity, or study completion.
|
Phase 1a: Brimarafenib 25 mg
n=5 Participants
Participants received brimarafenib 25 mg orally on Day 1 and then daily from Day 4 onwards. Participants continued treatment until disease progression, unacceptable toxicity, or study completion.
|
Phase 1b: Group 1 (25 mg)
n=11 Participants
Participants with solid tumors harboring BRAF V600 mutations (excluding colorectal cancer \[CRC\]) who had progressed on prior BRAF and/or MEK (mitogen-activated protein kinase kinase) inhibition were randomized using Interactive Response Technology (IRT) to receive 25 mg of BGB-3245 once daily.
|
Phase 1b: Group 1 (40 mg Randomized)
n=13 Participants
Participants with solid tumors harboring BRAF V600 mutations (excluding CRC) who had progressed on prior BRAF and/or MEK inhibition were randomized using IRT to receive 40 mg of BGB-3245 once daily.
|
|---|---|---|---|---|---|---|---|---|---|---|
|
Clinical Benefit Rate (CBR)
|
66.7 Percentage of Participants
Interval 9.4 to 99.2
|
0 Percentage of Participants
Interval 0.0 to 60.2
|
30.8 Percentage of Participants
Interval 14.3 to 51.8
|
33.3 Percentage of Participants
Interval 4.3 to 77.7
|
50.0 Percentage of Participants
Interval 1.3 to 98.7
|
20.0 Percentage of Participants
Interval 2.5 to 55.6
|
14.3 Percentage of Participants
Interval 0.4 to 57.9
|
0 Percentage of Participants
Interval 0.0 to 52.2
|
18.2 Percentage of Participants
Interval 2.3 to 51.8
|
7.7 Percentage of Participants
Interval 0.2 to 36.0
|
SECONDARY outcome
Timeframe: From first dose until disease progression or death, Maximum treatment duration was 47 months Phase 1a and 25 months in Phase 1b.Population: Safety Population
PFS was defined as the time from randomization to the date of first documented disease progression per RECIST v1.1 or death from any cause, whichever occurred first. Median PFS was estimated using the Kaplan-Meier method.
Outcome measures
| Measure |
Phase 1a: Brimarafenib 60 mg
n=4 Participants
Participants received brimarafenib 60 mg orally on Day 1 and then daily from Day 4 onwards. Participants continued treatment until disease progression, unacceptable toxicity, or study completion.
|
Phase 1b: Group 1 (Brimarafenib 40 mg Non-Randomized)
n=6 Participants
Participants with solid tumors harboring BRAF V600 mutations (excluding CRC) enrolled under Protocol Version 4.0 were treated with 40 mg of brimarafenib once daily without randomization. Participants continued treatment until disease progression, unacceptable toxicity, or study completion.
|
Phase 1b: Group 2 (Brimarafenib 40 mg)
n=34 Participants
Participants with advanced solid tumors harboring BRAF Class II mutations or a BRAF fusion mutation were treated with 40 mg of brimarafenib once daily.
|
Phase 1a: Brimarafenib 40 mg
n=8 Participants
Participants received brimarafenib 40 mg orally on Day 1 and then daily from Day 4 onwards. Participants continued treatment until disease progression, unacceptable toxicity, or study completion.
|
Phase 1a: Brimarafenib 5 mg
n=4 Participants
Participants received brimarafenib 5 mg orally on Day 1 and then daily from Day 4 onwards. Participants continued treatment until disease progression, unacceptable toxicity, or study completion.
|
Phase 1a: Brimarafenib 10 mg
n=12 Participants
Participants received brimarafenib 10 mg orally on Day 1 and then daily from Day 4 onwards. Participants continued treatment until disease progression, unacceptable toxicity, or study completion.
|
Phase 1a: Brimarafenib 15 mg
n=7 Participants
Participants received brimarafenib 15 mg orally on Day 1 and then daily from Day 4 onwards. Participants continued treatment until disease progression, unacceptable toxicity, or study completion.
|
Phase 1a: Brimarafenib 25 mg
n=7 Participants
Participants received brimarafenib 25 mg orally on Day 1 and then daily from Day 4 onwards. Participants continued treatment until disease progression, unacceptable toxicity, or study completion.
|
Phase 1b: Group 1 (25 mg)
n=13 Participants
Participants with solid tumors harboring BRAF V600 mutations (excluding colorectal cancer \[CRC\]) who had progressed on prior BRAF and/or MEK (mitogen-activated protein kinase kinase) inhibition were randomized using Interactive Response Technology (IRT) to receive 25 mg of BGB-3245 once daily.
|
Phase 1b: Group 1 (40 mg Randomized)
n=14 Participants
Participants with solid tumors harboring BRAF V600 mutations (excluding CRC) who had progressed on prior BRAF and/or MEK inhibition were randomized using IRT to receive 40 mg of BGB-3245 once daily.
|
|---|---|---|---|---|---|---|---|---|---|---|
|
Progression-free Survival (PFS)
|
20.2 Months
Interval 3.5 to
Not evaluable due to an insufficient number of events at the time of analysis.
|
1.8 Months
Interval 1.8 to
Not evaluable due to an insufficient number of events at the time of analysis.
|
4.8 Months
Interval 1.8 to 10.2
|
4.9 Months
Interval 1.4 to 10.9
|
1.8 Months
Interval 0.4 to
Not evaluable due to an insufficient number of events at the time of analysis.
|
2.4 Months
Interval 1.7 to 10.0
|
3.8 Months
Interval 1.7 to
Not evaluable due to an insufficient number of events at the time of analysis.
|
3.7 Months
Interval 1.5 to
Not evaluable due to an insufficient number of events at the time of analysis.
|
3.5 Months
Interval 1.8 to
Not evaluable due to an insufficient number of events at the time of analysis.
|
4.1 Months
Interval 1.7 to 5.4
|
SECONDARY outcome
Timeframe: From first dose until disease progression or death, Maximum treatment duration was 47 months Phase 1a and 25 months in Phase 1b.Population: Efficacy evaluable population who achieved stable disease as their confirmed best overall response
DSD is defined as the time interval, in the absence of either confirmed CR or PR, between the date of the first administration of study drug and the first documented disease progression per RECIST v1.1 or death due to any cause, whichever occurred first.
Outcome measures
| Measure |
Phase 1a: Brimarafenib 60 mg
Participants received brimarafenib 60 mg orally on Day 1 and then daily from Day 4 onwards. Participants continued treatment until disease progression, unacceptable toxicity, or study completion.
|
Phase 1b: Group 1 (Brimarafenib 40 mg Non-Randomized)
Participants with solid tumors harboring BRAF V600 mutations (excluding CRC) enrolled under Protocol Version 4.0 were treated with 40 mg of brimarafenib once daily without randomization. Participants continued treatment until disease progression, unacceptable toxicity, or study completion.
|
Phase 1b: Group 2 (Brimarafenib 40 mg)
n=12 Participants
Participants with advanced solid tumors harboring BRAF Class II mutations or a BRAF fusion mutation were treated with 40 mg of brimarafenib once daily.
|
Phase 1a: Brimarafenib 40 mg
n=2 Participants
Participants received brimarafenib 40 mg orally on Day 1 and then daily from Day 4 onwards. Participants continued treatment until disease progression, unacceptable toxicity, or study completion.
|
Phase 1a: Brimarafenib 5 mg
n=1 Participants
Participants received brimarafenib 5 mg orally on Day 1 and then daily from Day 4 onwards. Participants continued treatment until disease progression, unacceptable toxicity, or study completion.
|
Phase 1a: Brimarafenib 10 mg
n=3 Participants
Participants received brimarafenib 10 mg orally on Day 1 and then daily from Day 4 onwards. Participants continued treatment until disease progression, unacceptable toxicity, or study completion.
|
Phase 1a: Brimarafenib 15 mg
n=3 Participants
Participants received brimarafenib 15 mg orally on Day 1 and then daily from Day 4 onwards. Participants continued treatment until disease progression, unacceptable toxicity, or study completion.
|
Phase 1a: Brimarafenib 25 mg
n=3 Participants
Participants received brimarafenib 25 mg orally on Day 1 and then daily from Day 4 onwards. Participants continued treatment until disease progression, unacceptable toxicity, or study completion.
|
Phase 1b: Group 1 (25 mg)
n=6 Participants
Participants with solid tumors harboring BRAF V600 mutations (excluding colorectal cancer \[CRC\]) who had progressed on prior BRAF and/or MEK (mitogen-activated protein kinase kinase) inhibition were randomized using Interactive Response Technology (IRT) to receive 25 mg of BGB-3245 once daily.
|
Phase 1b: Group 1 (40 mg Randomized)
n=8 Participants
Participants with solid tumors harboring BRAF V600 mutations (excluding CRC) who had progressed on prior BRAF and/or MEK inhibition were randomized using IRT to receive 40 mg of BGB-3245 once daily.
|
|---|---|---|---|---|---|---|---|---|---|---|
|
Duration of Stable Disease (DSD)
|
—
|
—
|
NA Months
insufficient number of participants with events
|
NA Months
insufficient number of participants with events
|
NA Months
insufficient number of participants with events
|
NA Months
insufficient number of participants with events
|
NA Months
insufficient number of participants with events
|
NA Months
insufficient number of participants with events
|
NA Months
insufficient number of participants with events
|
NA Months
insufficient number of participants with events
|
SECONDARY outcome
Timeframe: From first dose until death, maximum treatment duration was 25 months.Population: Efficacy Evaluable Population
DCR is defined as the percentage of participants with a best overall response of CR, PR, or SD per RECIST v1.1 criteria. DCR reflects the percentage of participants whose disease did not progress during the study, including those with confirmed responses and those with durable SD.
Outcome measures
| Measure |
Phase 1a: Brimarafenib 60 mg
Participants received brimarafenib 60 mg orally on Day 1 and then daily from Day 4 onwards. Participants continued treatment until disease progression, unacceptable toxicity, or study completion.
|
Phase 1b: Group 1 (Brimarafenib 40 mg Non-Randomized)
Participants with solid tumors harboring BRAF V600 mutations (excluding CRC) enrolled under Protocol Version 4.0 were treated with 40 mg of brimarafenib once daily without randomization. Participants continued treatment until disease progression, unacceptable toxicity, or study completion.
|
Phase 1b: Group 2 (Brimarafenib 40 mg)
Participants with advanced solid tumors harboring BRAF Class II mutations or a BRAF fusion mutation were treated with 40 mg of brimarafenib once daily.
|
Phase 1a: Brimarafenib 40 mg
Participants received brimarafenib 40 mg orally on Day 1 and then daily from Day 4 onwards. Participants continued treatment until disease progression, unacceptable toxicity, or study completion.
|
Phase 1a: Brimarafenib 5 mg
n=11 Participants
Participants received brimarafenib 5 mg orally on Day 1 and then daily from Day 4 onwards. Participants continued treatment until disease progression, unacceptable toxicity, or study completion.
|
Phase 1a: Brimarafenib 10 mg
n=13 Participants
Participants received brimarafenib 10 mg orally on Day 1 and then daily from Day 4 onwards. Participants continued treatment until disease progression, unacceptable toxicity, or study completion.
|
Phase 1a: Brimarafenib 15 mg
n=4 Participants
Participants received brimarafenib 15 mg orally on Day 1 and then daily from Day 4 onwards. Participants continued treatment until disease progression, unacceptable toxicity, or study completion.
|
Phase 1a: Brimarafenib 25 mg
n=26 Participants
Participants received brimarafenib 25 mg orally on Day 1 and then daily from Day 4 onwards. Participants continued treatment until disease progression, unacceptable toxicity, or study completion.
|
Phase 1b: Group 1 (25 mg)
Participants with solid tumors harboring BRAF V600 mutations (excluding colorectal cancer \[CRC\]) who had progressed on prior BRAF and/or MEK (mitogen-activated protein kinase kinase) inhibition were randomized using Interactive Response Technology (IRT) to receive 25 mg of BGB-3245 once daily.
|
Phase 1b: Group 1 (40 mg Randomized)
Participants with solid tumors harboring BRAF V600 mutations (excluding CRC) who had progressed on prior BRAF and/or MEK inhibition were randomized using IRT to receive 40 mg of BGB-3245 once daily.
|
|---|---|---|---|---|---|---|---|---|---|---|
|
Phase 1b: Disease Control Rate (DCR)
|
—
|
—
|
—
|
—
|
54.5 percentage of participants
Interval 23.4 to 83.3
|
69.2 percentage of participants
Interval 38.6 to 90.9
|
0 percentage of participants
Interval 0.0 to 60.2
|
65.4 percentage of participants
Interval 44.3 to 82.8
|
—
|
—
|
SECONDARY outcome
Timeframe: From first dose until death, assessed maximum treatment duration was 25 months.Population: Safety Population
OS was defined as the time from randomization to the date of death from any cause. Median OS was estimated using the Kaplan-Meier method.
Outcome measures
| Measure |
Phase 1a: Brimarafenib 60 mg
Participants received brimarafenib 60 mg orally on Day 1 and then daily from Day 4 onwards. Participants continued treatment until disease progression, unacceptable toxicity, or study completion.
|
Phase 1b: Group 1 (Brimarafenib 40 mg Non-Randomized)
Participants with solid tumors harboring BRAF V600 mutations (excluding CRC) enrolled under Protocol Version 4.0 were treated with 40 mg of brimarafenib once daily without randomization. Participants continued treatment until disease progression, unacceptable toxicity, or study completion.
|
Phase 1b: Group 2 (Brimarafenib 40 mg)
Participants with advanced solid tumors harboring BRAF Class II mutations or a BRAF fusion mutation were treated with 40 mg of brimarafenib once daily.
|
Phase 1a: Brimarafenib 40 mg
Participants received brimarafenib 40 mg orally on Day 1 and then daily from Day 4 onwards. Participants continued treatment until disease progression, unacceptable toxicity, or study completion.
|
Phase 1a: Brimarafenib 5 mg
n=13 Participants
Participants received brimarafenib 5 mg orally on Day 1 and then daily from Day 4 onwards. Participants continued treatment until disease progression, unacceptable toxicity, or study completion.
|
Phase 1a: Brimarafenib 10 mg
n=14 Participants
Participants received brimarafenib 10 mg orally on Day 1 and then daily from Day 4 onwards. Participants continued treatment until disease progression, unacceptable toxicity, or study completion.
|
Phase 1a: Brimarafenib 15 mg
n=6 Participants
Participants received brimarafenib 15 mg orally on Day 1 and then daily from Day 4 onwards. Participants continued treatment until disease progression, unacceptable toxicity, or study completion.
|
Phase 1a: Brimarafenib 25 mg
n=34 Participants
Participants received brimarafenib 25 mg orally on Day 1 and then daily from Day 4 onwards. Participants continued treatment until disease progression, unacceptable toxicity, or study completion.
|
Phase 1b: Group 1 (25 mg)
Participants with solid tumors harboring BRAF V600 mutations (excluding colorectal cancer \[CRC\]) who had progressed on prior BRAF and/or MEK (mitogen-activated protein kinase kinase) inhibition were randomized using Interactive Response Technology (IRT) to receive 25 mg of BGB-3245 once daily.
|
Phase 1b: Group 1 (40 mg Randomized)
Participants with solid tumors harboring BRAF V600 mutations (excluding CRC) who had progressed on prior BRAF and/or MEK inhibition were randomized using IRT to receive 40 mg of BGB-3245 once daily.
|
|---|---|---|---|---|---|---|---|---|---|---|
|
Phase 1b: Overall Survival (OS)
|
—
|
—
|
—
|
—
|
NA Months
The study was terminated early due to lack of clinical benefit. Per the revised Statistical Analysis Plan, tabulated efficacy analyses were ORR and PFS. Overall Survival was not prespecified for summary tabulation; therefore, no tabular results are available for this outcome
|
NA Months
The study was terminated early due to lack of clinical benefit. Per the revised Statistical Analysis Plan, tabulated efficacy analyses were ORR and PFS. Overall Survival was not prespecified for summary tabulation; therefore, no tabular results are available for this outcome
|
NA Months
The study was terminated early due to lack of clinical benefit. Per the revised Statistical Analysis Plan, tabulated efficacy analyses were ORR and PFS. Overall Survival was not prespecified for summary tabulation; therefore, no tabular results are available for this outcome
|
NA Months
The study was terminated early due to lack of clinical benefit. Per the revised Statistical Analysis Plan, tabulated efficacy analyses were ORR and PFS. Overall Survival was not prespecified for summary tabulation; therefore, no tabular results are available for this outcome
|
—
|
—
|
SECONDARY outcome
Timeframe: Predose on Cycle 1 Day 15; Cycle 2 Day 1, Cycle 3 Day 1, and Cycle 4 Day 1. Each cycle was 28 days.Population: Pharmacokinetic (PK) Parameter Population with available data at each time point. The PK Parameter Population includes all participants who received brimarafenib and had sufficient pharmacokinetic data to calculate at least one PK parameter.
Ctrough is the observed concentration at predose.
Outcome measures
| Measure |
Phase 1a: Brimarafenib 60 mg
n=3 Participants
Participants received brimarafenib 60 mg orally on Day 1 and then daily from Day 4 onwards. Participants continued treatment until disease progression, unacceptable toxicity, or study completion.
|
Phase 1b: Group 1 (Brimarafenib 40 mg Non-Randomized)
Participants with solid tumors harboring BRAF V600 mutations (excluding CRC) enrolled under Protocol Version 4.0 were treated with 40 mg of brimarafenib once daily without randomization. Participants continued treatment until disease progression, unacceptable toxicity, or study completion.
|
Phase 1b: Group 2 (Brimarafenib 40 mg)
Participants with advanced solid tumors harboring BRAF Class II mutations or a BRAF fusion mutation were treated with 40 mg of brimarafenib once daily.
|
Phase 1a: Brimarafenib 40 mg
n=6 Participants
Participants received brimarafenib 40 mg orally on Day 1 and then daily from Day 4 onwards. Participants continued treatment until disease progression, unacceptable toxicity, or study completion.
|
Phase 1a: Brimarafenib 5 mg
n=3 Participants
Participants received brimarafenib 5 mg orally on Day 1 and then daily from Day 4 onwards. Participants continued treatment until disease progression, unacceptable toxicity, or study completion.
|
Phase 1a: Brimarafenib 10 mg
n=10 Participants
Participants received brimarafenib 10 mg orally on Day 1 and then daily from Day 4 onwards. Participants continued treatment until disease progression, unacceptable toxicity, or study completion.
|
Phase 1a: Brimarafenib 15 mg
n=7 Participants
Participants received brimarafenib 15 mg orally on Day 1 and then daily from Day 4 onwards. Participants continued treatment until disease progression, unacceptable toxicity, or study completion.
|
Phase 1a: Brimarafenib 25 mg
n=5 Participants
Participants received brimarafenib 25 mg orally on Day 1 and then daily from Day 4 onwards. Participants continued treatment until disease progression, unacceptable toxicity, or study completion.
|
Phase 1b: Group 1 (25 mg)
Participants with solid tumors harboring BRAF V600 mutations (excluding colorectal cancer \[CRC\]) who had progressed on prior BRAF and/or MEK (mitogen-activated protein kinase kinase) inhibition were randomized using Interactive Response Technology (IRT) to receive 25 mg of BGB-3245 once daily.
|
Phase 1b: Group 1 (40 mg Randomized)
Participants with solid tumors harboring BRAF V600 mutations (excluding CRC) who had progressed on prior BRAF and/or MEK inhibition were randomized using IRT to receive 40 mg of BGB-3245 once daily.
|
|---|---|---|---|---|---|---|---|---|---|---|
|
Phase 1a: Trough Plasma Concentration (Ctrough) of Brimarafenib
Cycle 2 Day 1
|
—
|
—
|
—
|
2475.00 ng/mL
Standard Deviation 1707.404
|
374.33 ng/mL
Standard Deviation 231.172
|
618.00 ng/mL
Standard Deviation 258.238
|
1071.14 ng/mL
Standard Deviation 656.045
|
1482.60 ng/mL
Standard Deviation 713.042
|
—
|
—
|
|
Phase 1a: Trough Plasma Concentration (Ctrough) of Brimarafenib
Cycle 3 Day 1
|
—
|
—
|
—
|
1620.60 ng/mL
Standard Deviation 1232.569
|
—
|
742.29 ng/mL
Standard Deviation 183.939
|
1222.75 ng/mL
Standard Deviation 551.462
|
2068.25 ng/mL
Standard Deviation 1314.237
|
—
|
—
|
|
Phase 1a: Trough Plasma Concentration (Ctrough) of Brimarafenib
Cycle 4 Day 1
|
—
|
—
|
—
|
1723.00 ng/mL
Standard Deviation 1051.397
|
—
|
804.40 ng/mL
Standard Deviation 236.265
|
1500.00 ng/mL
Standard Deviation 476.550
|
2298.75 ng/mL
Standard Deviation 956.228
|
—
|
—
|
|
Phase 1a: Trough Plasma Concentration (Ctrough) of Brimarafenib
Cycle 1 Day 15
|
6320.00 ng/mL
Standard Deviation 1333.679
|
—
|
—
|
1564.33 ng/mL
Standard Deviation 1028.191
|
346.33 ng/mL
Standard Deviation 183.506
|
599.90 ng/mL
Standard Deviation 192.756
|
949.29 ng/mL
Standard Deviation 299.771
|
1492.60 ng/mL
Standard Deviation 746.380
|
—
|
—
|
SECONDARY outcome
Timeframe: Cycle 1 Day 1 (predose and 1, 2, 3, 4, 6, and 8 hours postdose); Cycle 1 Days 2, 3, 4, 8, and 15; Cycle 2 Day 1 (predose and 1, 2, 3, 4, 6, and 8 hours postdose)Population: PK Parameter Population
Outcome measures
| Measure |
Phase 1a: Brimarafenib 60 mg
n=4 Participants
Participants received brimarafenib 60 mg orally on Day 1 and then daily from Day 4 onwards. Participants continued treatment until disease progression, unacceptable toxicity, or study completion.
|
Phase 1b: Group 1 (Brimarafenib 40 mg Non-Randomized)
Participants with solid tumors harboring BRAF V600 mutations (excluding CRC) enrolled under Protocol Version 4.0 were treated with 40 mg of brimarafenib once daily without randomization. Participants continued treatment until disease progression, unacceptable toxicity, or study completion.
|
Phase 1b: Group 2 (Brimarafenib 40 mg)
Participants with advanced solid tumors harboring BRAF Class II mutations or a BRAF fusion mutation were treated with 40 mg of brimarafenib once daily.
|
Phase 1a: Brimarafenib 40 mg
n=8 Participants
Participants received brimarafenib 40 mg orally on Day 1 and then daily from Day 4 onwards. Participants continued treatment until disease progression, unacceptable toxicity, or study completion.
|
Phase 1a: Brimarafenib 5 mg
n=4 Participants
Participants received brimarafenib 5 mg orally on Day 1 and then daily from Day 4 onwards. Participants continued treatment until disease progression, unacceptable toxicity, or study completion.
|
Phase 1a: Brimarafenib 10 mg
n=12 Participants
Participants received brimarafenib 10 mg orally on Day 1 and then daily from Day 4 onwards. Participants continued treatment until disease progression, unacceptable toxicity, or study completion.
|
Phase 1a: Brimarafenib 15 mg
n=7 Participants
Participants received brimarafenib 15 mg orally on Day 1 and then daily from Day 4 onwards. Participants continued treatment until disease progression, unacceptable toxicity, or study completion.
|
Phase 1a: Brimarafenib 25 mg
n=7 Participants
Participants received brimarafenib 25 mg orally on Day 1 and then daily from Day 4 onwards. Participants continued treatment until disease progression, unacceptable toxicity, or study completion.
|
Phase 1b: Group 1 (25 mg)
Participants with solid tumors harboring BRAF V600 mutations (excluding colorectal cancer \[CRC\]) who had progressed on prior BRAF and/or MEK (mitogen-activated protein kinase kinase) inhibition were randomized using Interactive Response Technology (IRT) to receive 25 mg of BGB-3245 once daily.
|
Phase 1b: Group 1 (40 mg Randomized)
Participants with solid tumors harboring BRAF V600 mutations (excluding CRC) who had progressed on prior BRAF and/or MEK inhibition were randomized using IRT to receive 40 mg of BGB-3245 once daily.
|
|---|---|---|---|---|---|---|---|---|---|---|
|
Phase 1a: Area Under the Concentration-time Curve From Dosing to Time of Last Quantifiable Concentration (AUClast) of Brimarafenib
Cycle 1 Day 1
|
57825.0 h*ng/mL
Standard Deviation 16018.82
|
—
|
—
|
34750.0 h*ng/mL
Standard Deviation 12609.07
|
3406.8 h*ng/mL
Standard Deviation 1925.65
|
7496.7 h*ng/mL
Standard Deviation 1588.50
|
11388.3 h*ng/mL
Standard Deviation 4097.99
|
20714.3 h*ng/mL
Standard Deviation 6002.90
|
—
|
—
|
|
Phase 1a: Area Under the Concentration-time Curve From Dosing to Time of Last Quantifiable Concentration (AUClast) of Brimarafenib
Cycle 2 Day 1
|
—
|
—
|
—
|
19183.3 h*ng/mL
Standard Deviation 14309.91
|
2586.7 h*ng/mL
Standard Deviation 1341.28
|
5392.0 h*ng/mL
Standard Deviation 2032.08
|
9524.3 h*ng/mL
Standard Deviation 5102.67
|
11850.0 h*ng/mL
Standard Deviation 5515.27
|
—
|
—
|
SECONDARY outcome
Timeframe: Cycle 1 Day 1 (predose and 1, 2, 3, 4, 6, 8, and 24 hours postdose)Population: PK Parameter Population with available data
Outcome measures
| Measure |
Phase 1a: Brimarafenib 60 mg
n=4 Participants
Participants received brimarafenib 60 mg orally on Day 1 and then daily from Day 4 onwards. Participants continued treatment until disease progression, unacceptable toxicity, or study completion.
|
Phase 1b: Group 1 (Brimarafenib 40 mg Non-Randomized)
Participants with solid tumors harboring BRAF V600 mutations (excluding CRC) enrolled under Protocol Version 4.0 were treated with 40 mg of brimarafenib once daily without randomization. Participants continued treatment until disease progression, unacceptable toxicity, or study completion.
|
Phase 1b: Group 2 (Brimarafenib 40 mg)
Participants with advanced solid tumors harboring BRAF Class II mutations or a BRAF fusion mutation were treated with 40 mg of brimarafenib once daily.
|
Phase 1a: Brimarafenib 40 mg
n=8 Participants
Participants received brimarafenib 40 mg orally on Day 1 and then daily from Day 4 onwards. Participants continued treatment until disease progression, unacceptable toxicity, or study completion.
|
Phase 1a: Brimarafenib 5 mg
n=4 Participants
Participants received brimarafenib 5 mg orally on Day 1 and then daily from Day 4 onwards. Participants continued treatment until disease progression, unacceptable toxicity, or study completion.
|
Phase 1a: Brimarafenib 10 mg
n=12 Participants
Participants received brimarafenib 10 mg orally on Day 1 and then daily from Day 4 onwards. Participants continued treatment until disease progression, unacceptable toxicity, or study completion.
|
Phase 1a: Brimarafenib 15 mg
n=6 Participants
Participants received brimarafenib 15 mg orally on Day 1 and then daily from Day 4 onwards. Participants continued treatment until disease progression, unacceptable toxicity, or study completion.
|
Phase 1a: Brimarafenib 25 mg
n=7 Participants
Participants received brimarafenib 25 mg orally on Day 1 and then daily from Day 4 onwards. Participants continued treatment until disease progression, unacceptable toxicity, or study completion.
|
Phase 1b: Group 1 (25 mg)
Participants with solid tumors harboring BRAF V600 mutations (excluding colorectal cancer \[CRC\]) who had progressed on prior BRAF and/or MEK (mitogen-activated protein kinase kinase) inhibition were randomized using Interactive Response Technology (IRT) to receive 25 mg of BGB-3245 once daily.
|
Phase 1b: Group 1 (40 mg Randomized)
Participants with solid tumors harboring BRAF V600 mutations (excluding CRC) who had progressed on prior BRAF and/or MEK inhibition were randomized using IRT to receive 40 mg of BGB-3245 once daily.
|
|---|---|---|---|---|---|---|---|---|---|---|
|
Phase 1a: Area Under the Concentration-time Curve From Dosing Time to Time Tau (Tau=24 Hours) of Brimarafenib
|
22350.0 h*ng/mL
Standard Deviation 8781.23
|
—
|
—
|
13868.8 h*ng/mL
Standard Deviation 4279.76
|
1399.0 h*ng/mL
Standard Deviation 851.38
|
3130.8 h*ng/mL
Standard Deviation 646.72
|
4705.0 h*ng/mL
Standard Deviation 1346.81
|
9111.4 h*ng/mL
Standard Deviation 3316.17
|
—
|
—
|
SECONDARY outcome
Timeframe: Cycle 1 Day 1 (predose and 1, 2, 3, 4, 6, 8, 24, 48, and 72 hours postdose)Population: PK Parameter Population with available data. AUC0-inf was calculated for participants with sufficient concentration-time data to reliably characterize the terminal elimination phase. For the 5 mg and 60 mg dose groups, insufficient data were available to estimate the terminal phase; therefore, AUC0-inf could not be calculated, and no participants were included in the analysis for these groups.
Outcome measures
| Measure |
Phase 1a: Brimarafenib 60 mg
Participants received brimarafenib 60 mg orally on Day 1 and then daily from Day 4 onwards. Participants continued treatment until disease progression, unacceptable toxicity, or study completion.
|
Phase 1b: Group 1 (Brimarafenib 40 mg Non-Randomized)
Participants with solid tumors harboring BRAF V600 mutations (excluding CRC) enrolled under Protocol Version 4.0 were treated with 40 mg of brimarafenib once daily without randomization. Participants continued treatment until disease progression, unacceptable toxicity, or study completion.
|
Phase 1b: Group 2 (Brimarafenib 40 mg)
Participants with advanced solid tumors harboring BRAF Class II mutations or a BRAF fusion mutation were treated with 40 mg of brimarafenib once daily.
|
Phase 1a: Brimarafenib 40 mg
n=6 Participants
Participants received brimarafenib 40 mg orally on Day 1 and then daily from Day 4 onwards. Participants continued treatment until disease progression, unacceptable toxicity, or study completion.
|
Phase 1a: Brimarafenib 5 mg
Participants received brimarafenib 5 mg orally on Day 1 and then daily from Day 4 onwards. Participants continued treatment until disease progression, unacceptable toxicity, or study completion.
|
Phase 1a: Brimarafenib 10 mg
n=8 Participants
Participants received brimarafenib 10 mg orally on Day 1 and then daily from Day 4 onwards. Participants continued treatment until disease progression, unacceptable toxicity, or study completion.
|
Phase 1a: Brimarafenib 15 mg
n=3 Participants
Participants received brimarafenib 15 mg orally on Day 1 and then daily from Day 4 onwards. Participants continued treatment until disease progression, unacceptable toxicity, or study completion.
|
Phase 1a: Brimarafenib 25 mg
n=5 Participants
Participants received brimarafenib 25 mg orally on Day 1 and then daily from Day 4 onwards. Participants continued treatment until disease progression, unacceptable toxicity, or study completion.
|
Phase 1b: Group 1 (25 mg)
Participants with solid tumors harboring BRAF V600 mutations (excluding colorectal cancer \[CRC\]) who had progressed on prior BRAF and/or MEK (mitogen-activated protein kinase kinase) inhibition were randomized using Interactive Response Technology (IRT) to receive 25 mg of BGB-3245 once daily.
|
Phase 1b: Group 1 (40 mg Randomized)
Participants with solid tumors harboring BRAF V600 mutations (excluding CRC) who had progressed on prior BRAF and/or MEK inhibition were randomized using IRT to receive 40 mg of BGB-3245 once daily.
|
|---|---|---|---|---|---|---|---|---|---|---|
|
Phase 1a: Area Under the Concentration-time Curve From Dosing Extrapolated to Infinity (AUC0-inf) of Brimarafenib
|
—
|
—
|
—
|
57083.3 h*ng/mL
Standard Deviation 39566.83
|
—
|
11671.3 h*ng/mL
Standard Deviation 3117.55
|
18866.7 h*ng/mL
Standard Deviation 5936.61
|
43420.0 h*ng/mL
Standard Deviation 21848.50
|
—
|
—
|
SECONDARY outcome
Timeframe: Cycle 1 Day 1 (predose and 1, 2, 3, 4, 6, 8, 24, 48, and 72 hours postdose); Cycle 2 Day 1 (predose and 1, 2, 3, 4, 6, and 8 hours postdose)Population: PK Parameter Population
Outcome measures
| Measure |
Phase 1a: Brimarafenib 60 mg
n=4 Participants
Participants received brimarafenib 60 mg orally on Day 1 and then daily from Day 4 onwards. Participants continued treatment until disease progression, unacceptable toxicity, or study completion.
|
Phase 1b: Group 1 (Brimarafenib 40 mg Non-Randomized)
Participants with solid tumors harboring BRAF V600 mutations (excluding CRC) enrolled under Protocol Version 4.0 were treated with 40 mg of brimarafenib once daily without randomization. Participants continued treatment until disease progression, unacceptable toxicity, or study completion.
|
Phase 1b: Group 2 (Brimarafenib 40 mg)
Participants with advanced solid tumors harboring BRAF Class II mutations or a BRAF fusion mutation were treated with 40 mg of brimarafenib once daily.
|
Phase 1a: Brimarafenib 40 mg
n=8 Participants
Participants received brimarafenib 40 mg orally on Day 1 and then daily from Day 4 onwards. Participants continued treatment until disease progression, unacceptable toxicity, or study completion.
|
Phase 1a: Brimarafenib 5 mg
n=4 Participants
Participants received brimarafenib 5 mg orally on Day 1 and then daily from Day 4 onwards. Participants continued treatment until disease progression, unacceptable toxicity, or study completion.
|
Phase 1a: Brimarafenib 10 mg
n=12 Participants
Participants received brimarafenib 10 mg orally on Day 1 and then daily from Day 4 onwards. Participants continued treatment until disease progression, unacceptable toxicity, or study completion.
|
Phase 1a: Brimarafenib 15 mg
n=7 Participants
Participants received brimarafenib 15 mg orally on Day 1 and then daily from Day 4 onwards. Participants continued treatment until disease progression, unacceptable toxicity, or study completion.
|
Phase 1a: Brimarafenib 25 mg
n=7 Participants
Participants received brimarafenib 25 mg orally on Day 1 and then daily from Day 4 onwards. Participants continued treatment until disease progression, unacceptable toxicity, or study completion.
|
Phase 1b: Group 1 (25 mg)
Participants with solid tumors harboring BRAF V600 mutations (excluding colorectal cancer \[CRC\]) who had progressed on prior BRAF and/or MEK (mitogen-activated protein kinase kinase) inhibition were randomized using Interactive Response Technology (IRT) to receive 25 mg of BGB-3245 once daily.
|
Phase 1b: Group 1 (40 mg Randomized)
Participants with solid tumors harboring BRAF V600 mutations (excluding CRC) who had progressed on prior BRAF and/or MEK inhibition were randomized using IRT to receive 40 mg of BGB-3245 once daily.
|
|---|---|---|---|---|---|---|---|---|---|---|
|
Phase 1a: Maximum Observed Plasma Concentration (Cmax) of Brimarafenib
Cycle 1 Day 1
|
1215.25 ng/mL
Standard Deviation 393.673
|
—
|
—
|
877.50 ng/mL
Standard Deviation 345.983
|
105.05 ng/mL
Standard Deviation 66.829
|
196.67 ng/mL
Standard Deviation 37.727
|
280.67 ng/mL
Standard Deviation 104.178
|
593.14 ng/mL
Standard Deviation 216.337
|
—
|
—
|
|
Phase 1a: Maximum Observed Plasma Concentration (Cmax) of Brimarafenib
Cycle 2 Day 1
|
—
|
—
|
—
|
3548.33 ng/mL
Standard Deviation 1872.703
|
451.33 ng/mL
Standard Deviation 277.237
|
970.80 ng/mL
Standard Deviation 400.301
|
1614.14 ng/mL
Standard Deviation 698.730
|
2112.00 ng/mL
Standard Deviation 844.701
|
—
|
—
|
SECONDARY outcome
Timeframe: Cycle 1 Day 1 (predose and 1, 2, 3, 4, 6, a 8, 24, 48, and 72 hours postdose); Cycle 2 Day 1 (predose and 1, 2, 3, 4, 6, and 8 hours postdose)Population: PK Parameter Population with available data at each time point
Outcome measures
| Measure |
Phase 1a: Brimarafenib 60 mg
n=4 Participants
Participants received brimarafenib 60 mg orally on Day 1 and then daily from Day 4 onwards. Participants continued treatment until disease progression, unacceptable toxicity, or study completion.
|
Phase 1b: Group 1 (Brimarafenib 40 mg Non-Randomized)
Participants with solid tumors harboring BRAF V600 mutations (excluding CRC) enrolled under Protocol Version 4.0 were treated with 40 mg of brimarafenib once daily without randomization. Participants continued treatment until disease progression, unacceptable toxicity, or study completion.
|
Phase 1b: Group 2 (Brimarafenib 40 mg)
Participants with advanced solid tumors harboring BRAF Class II mutations or a BRAF fusion mutation were treated with 40 mg of brimarafenib once daily.
|
Phase 1a: Brimarafenib 40 mg
n=8 Participants
Participants received brimarafenib 40 mg orally on Day 1 and then daily from Day 4 onwards. Participants continued treatment until disease progression, unacceptable toxicity, or study completion.
|
Phase 1a: Brimarafenib 5 mg
n=4 Participants
Participants received brimarafenib 5 mg orally on Day 1 and then daily from Day 4 onwards. Participants continued treatment until disease progression, unacceptable toxicity, or study completion.
|
Phase 1a: Brimarafenib 10 mg
n=12 Participants
Participants received brimarafenib 10 mg orally on Day 1 and then daily from Day 4 onwards. Participants continued treatment until disease progression, unacceptable toxicity, or study completion.
|
Phase 1a: Brimarafenib 15 mg
n=7 Participants
Participants received brimarafenib 15 mg orally on Day 1 and then daily from Day 4 onwards. Participants continued treatment until disease progression, unacceptable toxicity, or study completion.
|
Phase 1a: Brimarafenib 25 mg
n=7 Participants
Participants received brimarafenib 25 mg orally on Day 1 and then daily from Day 4 onwards. Participants continued treatment until disease progression, unacceptable toxicity, or study completion.
|
Phase 1b: Group 1 (25 mg)
Participants with solid tumors harboring BRAF V600 mutations (excluding colorectal cancer \[CRC\]) who had progressed on prior BRAF and/or MEK (mitogen-activated protein kinase kinase) inhibition were randomized using Interactive Response Technology (IRT) to receive 25 mg of BGB-3245 once daily.
|
Phase 1b: Group 1 (40 mg Randomized)
Participants with solid tumors harboring BRAF V600 mutations (excluding CRC) who had progressed on prior BRAF and/or MEK inhibition were randomized using IRT to receive 40 mg of BGB-3245 once daily.
|
|---|---|---|---|---|---|---|---|---|---|---|
|
Phase 1a: Time to Maximum Observed Plasma Concentration (Tmax) of Brimarafenib
Cycle 1 Day 1
|
8.05 hours
Interval 3.5 to 47.33
|
—
|
—
|
2.36 hours
Interval 2.02 to 5.95
|
6.89 hours
Interval 2.02 to 24.92
|
2.10 hours
Interval 0.87 to 7.83
|
2.25 hours
Interval 1.0 to 24.42
|
2.07 hours
Interval 2.03 to 6.12
|
—
|
—
|
|
Phase 1a: Time to Maximum Observed Plasma Concentration (Tmax) of Brimarafenib
Cycle 2 Day 1
|
—
|
—
|
—
|
1.80 hours
Interval 0.87 to 3.0
|
1.05 hours
Interval 0.97 to 4.08
|
1.22 hours
Interval 0.0 to 7.58
|
2.15 hours
Interval 1.0 to 5.43
|
1.05 hours
Interval 0.0 to 4.33
|
—
|
—
|
SECONDARY outcome
Timeframe: Cycle 1 Day 1 (predose and 1, 2, 3, 4, 6, 8, 24, 48, and 72 hours postdose)Population: PK Parameter Population with available data. Elimination half life was calculated for participants with sufficient concentration-time data to reliably characterize the terminal elimination phase. For the 5 mg and 60 mg dose groups, insufficient data were available to estimate the terminal phase; therefore, the elimination half life could not be calculated, and no participants were included in the analysis for these groups.
Outcome measures
| Measure |
Phase 1a: Brimarafenib 60 mg
Participants received brimarafenib 60 mg orally on Day 1 and then daily from Day 4 onwards. Participants continued treatment until disease progression, unacceptable toxicity, or study completion.
|
Phase 1b: Group 1 (Brimarafenib 40 mg Non-Randomized)
Participants with solid tumors harboring BRAF V600 mutations (excluding CRC) enrolled under Protocol Version 4.0 were treated with 40 mg of brimarafenib once daily without randomization. Participants continued treatment until disease progression, unacceptable toxicity, or study completion.
|
Phase 1b: Group 2 (Brimarafenib 40 mg)
Participants with advanced solid tumors harboring BRAF Class II mutations or a BRAF fusion mutation were treated with 40 mg of brimarafenib once daily.
|
Phase 1a: Brimarafenib 40 mg
n=6 Participants
Participants received brimarafenib 40 mg orally on Day 1 and then daily from Day 4 onwards. Participants continued treatment until disease progression, unacceptable toxicity, or study completion.
|
Phase 1a: Brimarafenib 5 mg
Participants received brimarafenib 5 mg orally on Day 1 and then daily from Day 4 onwards. Participants continued treatment until disease progression, unacceptable toxicity, or study completion.
|
Phase 1a: Brimarafenib 10 mg
n=8 Participants
Participants received brimarafenib 10 mg orally on Day 1 and then daily from Day 4 onwards. Participants continued treatment until disease progression, unacceptable toxicity, or study completion.
|
Phase 1a: Brimarafenib 15 mg
n=3 Participants
Participants received brimarafenib 15 mg orally on Day 1 and then daily from Day 4 onwards. Participants continued treatment until disease progression, unacceptable toxicity, or study completion.
|
Phase 1a: Brimarafenib 25 mg
n=5 Participants
Participants received brimarafenib 25 mg orally on Day 1 and then daily from Day 4 onwards. Participants continued treatment until disease progression, unacceptable toxicity, or study completion.
|
Phase 1b: Group 1 (25 mg)
Participants with solid tumors harboring BRAF V600 mutations (excluding colorectal cancer \[CRC\]) who had progressed on prior BRAF and/or MEK (mitogen-activated protein kinase kinase) inhibition were randomized using Interactive Response Technology (IRT) to receive 25 mg of BGB-3245 once daily.
|
Phase 1b: Group 1 (40 mg Randomized)
Participants with solid tumors harboring BRAF V600 mutations (excluding CRC) who had progressed on prior BRAF and/or MEK inhibition were randomized using IRT to receive 40 mg of BGB-3245 once daily.
|
|---|---|---|---|---|---|---|---|---|---|---|
|
Phase 1a: Elimination Half-Life (t½) of Brimarafenib
|
—
|
—
|
—
|
54.57 hours
Standard Deviation 24.939
|
—
|
48.64 hours
Standard Deviation 29.249
|
55.30 hours
Standard Deviation 12.401
|
58.90 hours
Standard Deviation 23.341
|
—
|
—
|
SECONDARY outcome
Timeframe: Cycle 1 Day 1 (predose and 1, 2, 3, 4, 6, 8, 24, 48, and 72 hours postdose)Population: PK Parameter Population with available data. Oral clearance was calculated for participants with sufficient concentration-time data to reliably characterize the terminal elimination phase. For the 5 mg and 60 mg dose groups, insufficient data were available to estimate the terminal phase; therefore, Oral clearance could not be calculated, and no participants were included in the analysis for these groups.
Outcome measures
| Measure |
Phase 1a: Brimarafenib 60 mg
Participants received brimarafenib 60 mg orally on Day 1 and then daily from Day 4 onwards. Participants continued treatment until disease progression, unacceptable toxicity, or study completion.
|
Phase 1b: Group 1 (Brimarafenib 40 mg Non-Randomized)
Participants with solid tumors harboring BRAF V600 mutations (excluding CRC) enrolled under Protocol Version 4.0 were treated with 40 mg of brimarafenib once daily without randomization. Participants continued treatment until disease progression, unacceptable toxicity, or study completion.
|
Phase 1b: Group 2 (Brimarafenib 40 mg)
Participants with advanced solid tumors harboring BRAF Class II mutations or a BRAF fusion mutation were treated with 40 mg of brimarafenib once daily.
|
Phase 1a: Brimarafenib 40 mg
n=6 Participants
Participants received brimarafenib 40 mg orally on Day 1 and then daily from Day 4 onwards. Participants continued treatment until disease progression, unacceptable toxicity, or study completion.
|
Phase 1a: Brimarafenib 5 mg
Participants received brimarafenib 5 mg orally on Day 1 and then daily from Day 4 onwards. Participants continued treatment until disease progression, unacceptable toxicity, or study completion.
|
Phase 1a: Brimarafenib 10 mg
n=8 Participants
Participants received brimarafenib 10 mg orally on Day 1 and then daily from Day 4 onwards. Participants continued treatment until disease progression, unacceptable toxicity, or study completion.
|
Phase 1a: Brimarafenib 15 mg
n=3 Participants
Participants received brimarafenib 15 mg orally on Day 1 and then daily from Day 4 onwards. Participants continued treatment until disease progression, unacceptable toxicity, or study completion.
|
Phase 1a: Brimarafenib 25 mg
n=5 Participants
Participants received brimarafenib 25 mg orally on Day 1 and then daily from Day 4 onwards. Participants continued treatment until disease progression, unacceptable toxicity, or study completion.
|
Phase 1b: Group 1 (25 mg)
Participants with solid tumors harboring BRAF V600 mutations (excluding colorectal cancer \[CRC\]) who had progressed on prior BRAF and/or MEK (mitogen-activated protein kinase kinase) inhibition were randomized using Interactive Response Technology (IRT) to receive 25 mg of BGB-3245 once daily.
|
Phase 1b: Group 1 (40 mg Randomized)
Participants with solid tumors harboring BRAF V600 mutations (excluding CRC) who had progressed on prior BRAF and/or MEK inhibition were randomized using IRT to receive 40 mg of BGB-3245 once daily.
|
|---|---|---|---|---|---|---|---|---|---|---|
|
Phase 1a: Apparent Oral Clearance (CL/F) of Brimarafenib
|
—
|
—
|
—
|
0.8887 L/h
Standard Deviation 0.35305
|
—
|
0.9125 L/h
Standard Deviation 0.24982
|
0.8470 L/h
Standard Deviation 0.25300
|
0.6802 L/h
Standard Deviation 0.26699
|
—
|
—
|
SECONDARY outcome
Timeframe: Cycle 1 Day 1 (predose and 1, 2, 3, 4, 6, 8, 24, 48, and 72 hours postdose)Population: PK Parameter Population with available data. Oral volume of distribution was calculated for participants with sufficient concentration-time data to reliably characterize the terminal elimination phase. For the 5 mg and 60 mg dose groups, insufficient data were available to estimate the terminal phase; therefore, oral volume of distribution could not be calculated, and no participants were included in the analysis for these groups.
Outcome measures
| Measure |
Phase 1a: Brimarafenib 60 mg
Participants received brimarafenib 60 mg orally on Day 1 and then daily from Day 4 onwards. Participants continued treatment until disease progression, unacceptable toxicity, or study completion.
|
Phase 1b: Group 1 (Brimarafenib 40 mg Non-Randomized)
Participants with solid tumors harboring BRAF V600 mutations (excluding CRC) enrolled under Protocol Version 4.0 were treated with 40 mg of brimarafenib once daily without randomization. Participants continued treatment until disease progression, unacceptable toxicity, or study completion.
|
Phase 1b: Group 2 (Brimarafenib 40 mg)
Participants with advanced solid tumors harboring BRAF Class II mutations or a BRAF fusion mutation were treated with 40 mg of brimarafenib once daily.
|
Phase 1a: Brimarafenib 40 mg
n=6 Participants
Participants received brimarafenib 40 mg orally on Day 1 and then daily from Day 4 onwards. Participants continued treatment until disease progression, unacceptable toxicity, or study completion.
|
Phase 1a: Brimarafenib 5 mg
Participants received brimarafenib 5 mg orally on Day 1 and then daily from Day 4 onwards. Participants continued treatment until disease progression, unacceptable toxicity, or study completion.
|
Phase 1a: Brimarafenib 10 mg
n=8 Participants
Participants received brimarafenib 10 mg orally on Day 1 and then daily from Day 4 onwards. Participants continued treatment until disease progression, unacceptable toxicity, or study completion.
|
Phase 1a: Brimarafenib 15 mg
n=3 Participants
Participants received brimarafenib 15 mg orally on Day 1 and then daily from Day 4 onwards. Participants continued treatment until disease progression, unacceptable toxicity, or study completion.
|
Phase 1a: Brimarafenib 25 mg
n=5 Participants
Participants received brimarafenib 25 mg orally on Day 1 and then daily from Day 4 onwards. Participants continued treatment until disease progression, unacceptable toxicity, or study completion.
|
Phase 1b: Group 1 (25 mg)
Participants with solid tumors harboring BRAF V600 mutations (excluding colorectal cancer \[CRC\]) who had progressed on prior BRAF and/or MEK (mitogen-activated protein kinase kinase) inhibition were randomized using Interactive Response Technology (IRT) to receive 25 mg of BGB-3245 once daily.
|
Phase 1b: Group 1 (40 mg Randomized)
Participants with solid tumors harboring BRAF V600 mutations (excluding CRC) who had progressed on prior BRAF and/or MEK inhibition were randomized using IRT to receive 40 mg of BGB-3245 once daily.
|
|---|---|---|---|---|---|---|---|---|---|---|
|
Phase 1a: Apparent Oral Volume of Distribution (Vz/F) of Brimarafenib
|
—
|
—
|
—
|
61.10 L
Standard Deviation 18.586
|
—
|
58.60 L
Standard Deviation 20.844
|
66.17 L
Standard Deviation 18.936
|
52.90 L
Standard Deviation 16.698
|
—
|
—
|
SECONDARY outcome
Timeframe: C1D1 (predose, 1, 3h postdose); C1D3, D8, D22 (±2d; predose, 2-4h postdose on D22); C2D1 (predose, 1, 3h); C3, 4, 6, 8, 10, 12 D1 and every 3rd cycle (predose); and at treatment discontinuation (2-4h).Population: PK Parameter Population with available data. Plasma concentration summaries are presented for participants with evaluable PK samples at the specified time points. No evaluable PK concentration data were available for the Phase 1b 25 mg dose group arm; therefore, this arm is not included in the analysis.
Outcome measures
| Measure |
Phase 1a: Brimarafenib 60 mg
Participants received brimarafenib 60 mg orally on Day 1 and then daily from Day 4 onwards. Participants continued treatment until disease progression, unacceptable toxicity, or study completion.
|
Phase 1b: Group 1 (Brimarafenib 40 mg Non-Randomized)
Participants with solid tumors harboring BRAF V600 mutations (excluding CRC) enrolled under Protocol Version 4.0 were treated with 40 mg of brimarafenib once daily without randomization. Participants continued treatment until disease progression, unacceptable toxicity, or study completion.
|
Phase 1b: Group 2 (Brimarafenib 40 mg)
Participants with advanced solid tumors harboring BRAF Class II mutations or a BRAF fusion mutation were treated with 40 mg of brimarafenib once daily.
|
Phase 1a: Brimarafenib 40 mg
Participants received brimarafenib 40 mg orally on Day 1 and then daily from Day 4 onwards. Participants continued treatment until disease progression, unacceptable toxicity, or study completion.
|
Phase 1a: Brimarafenib 5 mg
Participants received brimarafenib 5 mg orally on Day 1 and then daily from Day 4 onwards. Participants continued treatment until disease progression, unacceptable toxicity, or study completion.
|
Phase 1a: Brimarafenib 10 mg
n=2 Participants
Participants received brimarafenib 10 mg orally on Day 1 and then daily from Day 4 onwards. Participants continued treatment until disease progression, unacceptable toxicity, or study completion.
|
Phase 1a: Brimarafenib 15 mg
n=6 Participants
Participants received brimarafenib 15 mg orally on Day 1 and then daily from Day 4 onwards. Participants continued treatment until disease progression, unacceptable toxicity, or study completion.
|
Phase 1a: Brimarafenib 25 mg
n=18 Participants
Participants received brimarafenib 25 mg orally on Day 1 and then daily from Day 4 onwards. Participants continued treatment until disease progression, unacceptable toxicity, or study completion.
|
Phase 1b: Group 1 (25 mg)
Participants with solid tumors harboring BRAF V600 mutations (excluding colorectal cancer \[CRC\]) who had progressed on prior BRAF and/or MEK (mitogen-activated protein kinase kinase) inhibition were randomized using Interactive Response Technology (IRT) to receive 25 mg of BGB-3245 once daily.
|
Phase 1b: Group 1 (40 mg Randomized)
Participants with solid tumors harboring BRAF V600 mutations (excluding CRC) who had progressed on prior BRAF and/or MEK inhibition were randomized using IRT to receive 40 mg of BGB-3245 once daily.
|
|---|---|---|---|---|---|---|---|---|---|---|
|
Phase 1b: Plasma Concentrations for Brimarafenib
Cycle 1 Day 8
|
—
|
—
|
—
|
—
|
—
|
1832.5 ng/mL
Standard Deviation 1212.688
|
3615.00 ng/mL
Standard Deviation 1243.503
|
2084.24 ng/mL
Standard Deviation 757.622
|
—
|
—
|
|
Phase 1b: Plasma Concentrations for Brimarafenib
Cycle 1 Day 22
|
—
|
—
|
—
|
—
|
—
|
1656.0 ng/mL
Standard Deviation 1504.723
|
2085.67 ng/mL
Standard Deviation 1638.812
|
2176.25 ng/mL
Standard Deviation 1283.811
|
—
|
—
|
|
Phase 1b: Plasma Concentrations for Brimarafenib
Cycle 2 Day 1
|
—
|
—
|
—
|
—
|
—
|
600.00 ng/mL
|
2007.00 ng/mL
Standard Deviation 1934.896
|
1684.67 ng/mL
Standard Deviation 1729.221
|
—
|
—
|
SECONDARY outcome
Timeframe: From first dose until 30 days after last dose of study treatment. Maximum treatment duration was 25 months.Population: Safety population
SAEs were defined as events that resulted in death, were life-threatening, required or prolonged hospitalization, caused significant disability, or were considered important medical events.
Outcome measures
| Measure |
Phase 1a: Brimarafenib 60 mg
Participants received brimarafenib 60 mg orally on Day 1 and then daily from Day 4 onwards. Participants continued treatment until disease progression, unacceptable toxicity, or study completion.
|
Phase 1b: Group 1 (Brimarafenib 40 mg Non-Randomized)
Participants with solid tumors harboring BRAF V600 mutations (excluding CRC) enrolled under Protocol Version 4.0 were treated with 40 mg of brimarafenib once daily without randomization. Participants continued treatment until disease progression, unacceptable toxicity, or study completion.
|
Phase 1b: Group 2 (Brimarafenib 40 mg)
Participants with advanced solid tumors harboring BRAF Class II mutations or a BRAF fusion mutation were treated with 40 mg of brimarafenib once daily.
|
Phase 1a: Brimarafenib 40 mg
Participants received brimarafenib 40 mg orally on Day 1 and then daily from Day 4 onwards. Participants continued treatment until disease progression, unacceptable toxicity, or study completion.
|
Phase 1a: Brimarafenib 5 mg
n=13 Participants
Participants received brimarafenib 5 mg orally on Day 1 and then daily from Day 4 onwards. Participants continued treatment until disease progression, unacceptable toxicity, or study completion.
|
Phase 1a: Brimarafenib 10 mg
n=14 Participants
Participants received brimarafenib 10 mg orally on Day 1 and then daily from Day 4 onwards. Participants continued treatment until disease progression, unacceptable toxicity, or study completion.
|
Phase 1a: Brimarafenib 15 mg
n=6 Participants
Participants received brimarafenib 15 mg orally on Day 1 and then daily from Day 4 onwards. Participants continued treatment until disease progression, unacceptable toxicity, or study completion.
|
Phase 1a: Brimarafenib 25 mg
n=34 Participants
Participants received brimarafenib 25 mg orally on Day 1 and then daily from Day 4 onwards. Participants continued treatment until disease progression, unacceptable toxicity, or study completion.
|
Phase 1b: Group 1 (25 mg)
Participants with solid tumors harboring BRAF V600 mutations (excluding colorectal cancer \[CRC\]) who had progressed on prior BRAF and/or MEK (mitogen-activated protein kinase kinase) inhibition were randomized using Interactive Response Technology (IRT) to receive 25 mg of BGB-3245 once daily.
|
Phase 1b: Group 1 (40 mg Randomized)
Participants with solid tumors harboring BRAF V600 mutations (excluding CRC) who had progressed on prior BRAF and/or MEK inhibition were randomized using IRT to receive 40 mg of BGB-3245 once daily.
|
|---|---|---|---|---|---|---|---|---|---|---|
|
Phase 1b: Number of Participants Experiencing Treatment-Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)
At least one TEAE
|
—
|
—
|
—
|
—
|
13 Participants
|
14 Participants
|
6 Participants
|
34 Participants
|
—
|
—
|
|
Phase 1b: Number of Participants Experiencing Treatment-Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)
At least one SAE
|
—
|
—
|
—
|
—
|
8 Participants
|
6 Participants
|
4 Participants
|
30 Participants
|
—
|
—
|
Adverse Events
Phase 1a: Brimarafenib 60 mg
Serious events: 4 serious events
Other events: 4 other events
Deaths: 2 deaths
Phase 1b: Group 1 (Brimarafenib 25 mg)
Serious events: 8 serious events
Other events: 12 other events
Deaths: 3 deaths
Phase 1b: Group 1 (Brimarafenib 40 mg Randomized)
Serious events: 6 serious events
Other events: 14 other events
Deaths: 5 deaths
Phase 1a: Brimarafenib 5 mg
Serious events: 2 serious events
Other events: 4 other events
Deaths: 2 deaths
Phase 1a: Brimarafenib 10 mg
Serious events: 8 serious events
Other events: 12 other events
Deaths: 5 deaths
Phase 1a: Brimarafenib 15 mg
Serious events: 5 serious events
Other events: 7 other events
Deaths: 2 deaths
Phase 1a: Brimarafenib 25 mg
Serious events: 3 serious events
Other events: 7 other events
Deaths: 2 deaths
Phase 1a: Brimarafenib 40 mg
Serious events: 5 serious events
Other events: 8 other events
Deaths: 3 deaths
Phase 1b: Group 1 (Brimarafenib 40 mg Non-Randomized)
Serious events: 4 serious events
Other events: 6 other events
Deaths: 1 deaths
Phase 1b: Group 2 (Brimarafenib 40 mg)
Serious events: 30 serious events
Other events: 34 other events
Deaths: 19 deaths
Serious adverse events
| Measure |
Phase 1a: Brimarafenib 60 mg
n=4 participants at risk
Participants received brimarafenib 60 mg orally on Day 1 and then daily from Day 4 onwards. Participants continued treatment until disease progression, unacceptable toxicity, or study completion.
|
Phase 1b: Group 1 (Brimarafenib 25 mg)
n=13 participants at risk
Participants with solid tumors harboring BRAF V600 mutations (excluding colorectal cancer \[CRC\]) who had progressed on prior BRAF and/or MEK (mitogen-activated protein kinase) inhibition were randomized using Interactive Response Technology (IRT) to receive 25 mg of brimarafenib once daily. Participants continued treatment until disease progression, unacceptable toxicity, or study completion.
|
Phase 1b: Group 1 (Brimarafenib 40 mg Randomized)
n=14 participants at risk
Participants with solid tumors harboring BRAF V600 mutations (excluding CRC) who had progressed on prior BRAF and/or MEK inhibition were randomized using IRT to receive 40 mg of brimarafenib once daily. Participants continued treatment until disease progression, unacceptable toxicity, or study completion.
|
Phase 1a: Brimarafenib 5 mg
n=4 participants at risk
Participants received brimarafenib 5 mg orally on Day 1 and then daily from Day 4 onwards. Participants continued treatment until disease progression, unacceptable toxicity, or study completion.
|
Phase 1a: Brimarafenib 10 mg
n=12 participants at risk
Participants received brimarafenib 10 mg orally on Day 1 and then daily from Day 4 onwards. Participants continued treatment until disease progression, unacceptable toxicity, or study completion.
|
Phase 1a: Brimarafenib 15 mg
n=7 participants at risk
Participants received brimarafenib 15 mg orally on Day 1 and then daily from Day 4 onwards. Participants continued treatment until disease progression, unacceptable toxicity, or study completion.
|
Phase 1a: Brimarafenib 25 mg
n=7 participants at risk
Participants received brimarafenib 25 mg orally on Day 1 and then daily from Day 4 onwards. Participants continued treatment until disease progression, unacceptable toxicity, or study completion.
|
Phase 1a: Brimarafenib 40 mg
n=8 participants at risk
Participants received brimarafenib 40 mg orally on Day 1 and then daily from Day 4 onwards. Participants continued treatment until disease progression, unacceptable toxicity, or study completion.
|
Phase 1b: Group 1 (Brimarafenib 40 mg Non-Randomized)
n=6 participants at risk
Participants with solid tumors harboring BRAF V600 mutations (excluding CRC) enrolled under Protocol Version 4.0 were treated with 40 mg of brimarafenib once daily without randomization. Participants continued treatment until disease progression, unacceptable toxicity, or study completion.
|
Phase 1b: Group 2 (Brimarafenib 40 mg)
n=34 participants at risk
Participants with advanced solid tumors harboring Class II mutations or a BRAF fusion mutation were treated with 40 mg of brimarafenib once daily. Participants continued treatment until disease progression, unacceptable toxicity, or study completion.
|
|---|---|---|---|---|---|---|---|---|---|---|
|
General disorders
Pyrexia
|
25.0%
1/4 • Number of events 1 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
7.7%
1/13 • Number of events 1 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/14 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/4 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
8.3%
1/12 • Number of events 2 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/7 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
14.3%
1/7 • Number of events 1 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
25.0%
2/8 • Number of events 2 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
16.7%
1/6 • Number of events 1 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
11.8%
4/34 • Number of events 4 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
|
Gastrointestinal disorders
Abdominal pain
|
25.0%
1/4 • Number of events 1 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
7.7%
1/13 • Number of events 1 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/14 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/4 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/12 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
14.3%
1/7 • Number of events 1 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
14.3%
1/7 • Number of events 1 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/8 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/6 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
8.8%
3/34 • Number of events 3 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
|
Gastrointestinal disorders
Small intestinal obstruction
|
0.00%
0/4 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/13 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/14 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/4 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/12 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
28.6%
2/7 • Number of events 3 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/7 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/8 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/6 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/34 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
|
Gastrointestinal disorders
Colitis
|
0.00%
0/4 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/13 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/14 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/4 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
8.3%
1/12 • Number of events 1 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/7 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/7 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/8 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/6 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
2.9%
1/34 • Number of events 1 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
|
Gastrointestinal disorders
Constipation
|
0.00%
0/4 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/13 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/14 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/4 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
8.3%
1/12 • Number of events 1 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/7 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/7 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/8 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/6 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
2.9%
1/34 • Number of events 1 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
|
Gastrointestinal disorders
Intestinal ischaemia
|
0.00%
0/4 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/13 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/14 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/4 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/12 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
14.3%
1/7 • Number of events 1 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/7 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/8 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/6 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/34 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
|
Gastrointestinal disorders
Intestinal obstruction
|
0.00%
0/4 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/13 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/14 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
25.0%
1/4 • Number of events 1 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/12 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/7 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/7 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/8 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/6 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/34 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
|
Gastrointestinal disorders
Rectal haemorrhage
|
0.00%
0/4 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/13 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/14 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/4 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/12 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/7 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/7 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
12.5%
1/8 • Number of events 1 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/6 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/34 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
|
Infections and infestations
Pneumonia
|
0.00%
0/4 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/13 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/14 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/4 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
16.7%
2/12 • Number of events 2 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
28.6%
2/7 • Number of events 2 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/7 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/8 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
33.3%
2/6 • Number of events 2 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
14.7%
5/34 • Number of events 7 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
|
Infections and infestations
Skin infection
|
0.00%
0/4 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/13 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/14 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/4 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/12 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/7 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/7 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
12.5%
1/8 • Number of events 2 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/6 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/34 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
|
Infections and infestations
Abdominal wall abscess
|
0.00%
0/4 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/13 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/14 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/4 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/12 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
14.3%
1/7 • Number of events 1 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/7 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/8 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/6 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/34 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
|
Infections and infestations
Cellulitis
|
0.00%
0/4 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/13 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/14 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/4 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
8.3%
1/12 • Number of events 1 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/7 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/7 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/8 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/6 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/34 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
|
Infections and infestations
Clostridium difficile colitis
|
0.00%
0/4 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/13 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
7.1%
1/14 • Number of events 1 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/4 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/12 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
14.3%
1/7 • Number of events 1 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/7 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/8 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/6 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/34 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
|
Infections and infestations
Urinary tract infection
|
0.00%
0/4 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/13 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/14 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/4 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/12 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
14.3%
1/7 • Number of events 1 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/7 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/8 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/6 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/34 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
|
Infections and infestations
Wound infection
|
0.00%
0/4 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/13 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/14 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/4 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
8.3%
1/12 • Number of events 1 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/7 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/7 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/8 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/6 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/34 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
|
Respiratory, thoracic and mediastinal disorders
Dyspnoea
|
0.00%
0/4 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/13 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
7.1%
1/14 • Number of events 1 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/4 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/12 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/7 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
14.3%
1/7 • Number of events 1 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
12.5%
1/8 • Number of events 1 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/6 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
8.8%
3/34 • Number of events 5 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
|
Respiratory, thoracic and mediastinal disorders
Pleural effusion
|
0.00%
0/4 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/13 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/14 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/4 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
16.7%
2/12 • Number of events 2 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/7 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/7 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/8 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
16.7%
1/6 • Number of events 1 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/34 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
|
Respiratory, thoracic and mediastinal disorders
Pulmonary embolism
|
0.00%
0/4 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/13 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/14 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/4 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/12 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
14.3%
1/7 • Number of events 1 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
14.3%
1/7 • Number of events 1 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/8 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/6 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
2.9%
1/34 • Number of events 1 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
|
Respiratory, thoracic and mediastinal disorders
Pneumonitis
|
0.00%
0/4 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/13 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/14 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/4 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/12 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/7 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/7 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
12.5%
1/8 • Number of events 1 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/6 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/34 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
|
Respiratory, thoracic and mediastinal disorders
Pneumothorax
|
0.00%
0/4 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/13 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/14 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/4 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
8.3%
1/12 • Number of events 1 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/7 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/7 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/8 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/6 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/34 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
|
Respiratory, thoracic and mediastinal disorders
Respiratory failure
|
0.00%
0/4 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/13 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/14 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/4 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
8.3%
1/12 • Number of events 1 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/7 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/7 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/8 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/6 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
2.9%
1/34 • Number of events 1 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
|
General disorders
Oedema peripheral
|
0.00%
0/4 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/13 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/14 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/4 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/12 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
14.3%
1/7 • Number of events 1 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/7 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/8 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/6 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/34 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Tumour haemorrhage
|
0.00%
0/4 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/13 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/14 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/4 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
8.3%
1/12 • Number of events 2 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/7 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
14.3%
1/7 • Number of events 1 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/8 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/6 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/34 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Acute myeloid leukaemia
|
0.00%
0/4 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/13 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/14 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/4 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/12 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
14.3%
1/7 • Number of events 1 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/7 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/8 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/6 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/34 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
|
Vascular disorders
Embolism
|
0.00%
0/4 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/13 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/14 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/4 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/12 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/7 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/7 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
12.5%
1/8 • Number of events 1 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/6 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
2.9%
1/34 • Number of events 1 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Metastases to meninges
|
0.00%
0/4 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/13 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/14 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/4 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/12 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/7 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/7 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
12.5%
1/8 • Number of events 1 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/6 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/34 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Squamous cell carcinoma
|
0.00%
0/4 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/13 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/14 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/4 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
8.3%
1/12 • Number of events 1 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/7 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/7 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/8 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/6 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/34 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
|
Cardiac disorders
Atrial fibrillation
|
25.0%
1/4 • Number of events 1 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
7.7%
1/13 • Number of events 1 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
7.1%
1/14 • Number of events 1 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/4 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/12 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
14.3%
1/7 • Number of events 1 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/7 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
12.5%
1/8 • Number of events 2 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
16.7%
1/6 • Number of events 1 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
5.9%
2/34 • Number of events 2 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
|
Cardiac disorders
Sinus tachycardia
|
0.00%
0/4 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/13 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/14 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/4 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/12 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
14.3%
1/7 • Number of events 1 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/7 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/8 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/6 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/34 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
|
Investigations
Alanine aminotransferase increased
|
0.00%
0/4 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/13 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/14 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/4 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/12 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/7 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
14.3%
1/7 • Number of events 1 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/8 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/6 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/34 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
|
Investigations
Aspartate aminotransferase increased
|
0.00%
0/4 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/13 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/14 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/4 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/12 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/7 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
14.3%
1/7 • Number of events 1 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/8 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/6 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/34 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
|
Investigations
Electrocardiogram T wave abnormal
|
0.00%
0/4 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/13 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/14 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/4 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/12 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/7 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
14.3%
1/7 • Number of events 1 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/8 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/6 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/34 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
|
Investigations
Platelet count decreased
|
0.00%
0/4 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/13 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/14 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/4 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/12 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/7 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
14.3%
1/7 • Number of events 1 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/8 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/6 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
2.9%
1/34 • Number of events 1 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
|
Renal and urinary disorders
Acute kidney injury
|
25.0%
1/4 • Number of events 1 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
7.7%
1/13 • Number of events 1 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/14 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/4 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/12 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
14.3%
1/7 • Number of events 1 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/7 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/8 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/6 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
2.9%
1/34 • Number of events 1 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
|
Renal and urinary disorders
Ureteric obstruction
|
0.00%
0/4 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/13 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/14 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
25.0%
1/4 • Number of events 1 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/12 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/7 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/7 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/8 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/6 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/34 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
|
Renal and urinary disorders
Urinary retention
|
0.00%
0/4 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/13 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/14 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/4 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/12 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
14.3%
1/7 • Number of events 1 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/7 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/8 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/6 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
5.9%
2/34 • Number of events 2 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
|
Skin and subcutaneous tissue disorders
Angioedema
|
25.0%
1/4 • Number of events 1 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/13 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/14 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/4 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/12 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/7 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/7 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/8 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/6 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/34 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
|
Skin and subcutaneous tissue disorders
Drug reaction with eosinophilia and systemic symptoms
|
0.00%
0/4 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/13 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/14 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/4 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/12 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/7 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/7 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
12.5%
1/8 • Number of events 1 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/6 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/34 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
|
Skin and subcutaneous tissue disorders
Rash
|
25.0%
1/4 • Number of events 1 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/13 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/14 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/4 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/12 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/7 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/7 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/8 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/6 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/34 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
|
Skin and subcutaneous tissue disorders
Urticaria
|
0.00%
0/4 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/13 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/14 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/4 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/12 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/7 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
14.3%
1/7 • Number of events 1 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/8 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/6 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/34 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
|
Musculoskeletal and connective tissue disorders
Osteolysis
|
0.00%
0/4 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/13 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/14 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/4 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/12 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
14.3%
1/7 • Number of events 1 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/7 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/8 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/6 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/34 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
|
Musculoskeletal and connective tissue disorders
Rhabdomyolysis
|
25.0%
1/4 • Number of events 1 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/13 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/14 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/4 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/12 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/7 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/7 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/8 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/6 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/34 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
|
Immune system disorders
Hypersensitivity
|
0.00%
0/4 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/13 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/14 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/4 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
8.3%
1/12 • Number of events 1 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/7 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/7 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/8 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/6 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/34 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
|
Injury, poisoning and procedural complications
Spinal fracture
|
0.00%
0/4 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/13 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/14 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/4 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/12 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
14.3%
1/7 • Number of events 1 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/7 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/8 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/6 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/34 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
|
Metabolism and nutrition disorders
Dehydration
|
25.0%
1/4 • Number of events 1 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/13 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
7.1%
1/14 • Number of events 1 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/4 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/12 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/7 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/7 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/8 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/6 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/34 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
|
Nervous system disorders
Syncope
|
0.00%
0/4 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/13 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/14 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/4 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
8.3%
1/12 • Number of events 1 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/7 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/7 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/8 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/6 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/34 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
|
Blood and lymphatic system disorders
Anaemia
|
0.00%
0/4 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/13 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/14 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/4 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/12 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/7 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/7 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/8 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/6 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
2.9%
1/34 • Number of events 1 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
|
Blood and lymphatic system disorders
Disseminated intravascular coagulation
|
0.00%
0/4 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/13 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/14 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/4 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/12 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/7 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/7 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/8 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/6 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
2.9%
1/34 • Number of events 1 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
|
Blood and lymphatic system disorders
Pancytopenia
|
0.00%
0/4 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/13 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/14 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/4 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/12 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/7 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/7 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/8 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
16.7%
1/6 • Number of events 1 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/34 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
|
Blood and lymphatic system disorders
Thrombocytopenia
|
0.00%
0/4 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/13 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/14 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/4 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/12 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/7 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/7 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/8 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/6 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
2.9%
1/34 • Number of events 1 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
|
Cardiac disorders
Coronary artery disease
|
0.00%
0/4 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/13 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
7.1%
1/14 • Number of events 1 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/4 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/12 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/7 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/7 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/8 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/6 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/34 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
|
General disorders
Fatigue
|
0.00%
0/4 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/13 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/14 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/4 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/12 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/7 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/7 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/8 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/6 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
2.9%
1/34 • Number of events 1 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
|
Cardiac disorders
Left ventricular dysfunction
|
0.00%
0/4 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
7.7%
1/13 • Number of events 1 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/14 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/4 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/12 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/7 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/7 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/8 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/6 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/34 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
|
Cardiac disorders
Pericardial effusion
|
0.00%
0/4 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/13 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/14 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/4 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/12 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/7 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/7 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/8 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/6 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
2.9%
1/34 • Number of events 1 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
|
Cardiac disorders
Tachycardia
|
0.00%
0/4 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/13 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
7.1%
1/14 • Number of events 1 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/4 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/12 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/7 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/7 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/8 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/6 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/34 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
|
Gastrointestinal disorders
Ascites
|
0.00%
0/4 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/13 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/14 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/4 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/12 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/7 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/7 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/8 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/6 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
5.9%
2/34 • Number of events 2 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
|
Gastrointestinal disorders
Abdominal distension
|
0.00%
0/4 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/13 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/14 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/4 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/12 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/7 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/7 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/8 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/6 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
2.9%
1/34 • Number of events 3 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
|
Gastrointestinal disorders
Enterocolitis
|
0.00%
0/4 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/13 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
7.1%
1/14 • Number of events 1 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/4 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/12 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/7 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/7 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/8 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/6 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/34 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
|
Gastrointestinal disorders
Food poisoning
|
0.00%
0/4 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/13 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
7.1%
1/14 • Number of events 1 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/4 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/12 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/7 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/7 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/8 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/6 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/34 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
|
Gastrointestinal disorders
Hiatus hernia
|
0.00%
0/4 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/13 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/14 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/4 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/12 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/7 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/7 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/8 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/6 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
2.9%
1/34 • Number of events 1 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
|
Gastrointestinal disorders
Lower gastrointestinal haemorrhage
|
0.00%
0/4 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/13 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
7.1%
1/14 • Number of events 1 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/4 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/12 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/7 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/7 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/8 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/6 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/34 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
|
Gastrointestinal disorders
Nausea
|
0.00%
0/4 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/13 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/14 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/4 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/12 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/7 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/7 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/8 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/6 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
2.9%
1/34 • Number of events 1 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
|
General disorders
Influenza like illness
|
0.00%
0/4 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
7.7%
1/13 • Number of events 1 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/14 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/4 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/12 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/7 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/7 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/8 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/6 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/34 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
|
General disorders
Multiple organ dysfunction syndrome
|
0.00%
0/4 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/13 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/14 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/4 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/12 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/7 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/7 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/8 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/6 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
2.9%
1/34 • Number of events 1 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
|
General disorders
Non-cardiac chest pain
|
0.00%
0/4 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/13 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/14 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/4 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/12 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/7 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/7 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/8 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/6 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
2.9%
1/34 • Number of events 1 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
|
General disorders
Pain
|
0.00%
0/4 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/13 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/14 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/4 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/12 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/7 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/7 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/8 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/6 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
2.9%
1/34 • Number of events 1 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
|
Hepatobiliary disorders
Biliary obstruction
|
0.00%
0/4 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/13 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/14 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/4 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/12 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/7 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/7 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/8 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/6 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
2.9%
1/34 • Number of events 1 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
|
Hepatobiliary disorders
Hepatotoxicity
|
0.00%
0/4 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/13 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/14 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/4 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/12 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/7 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/7 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/8 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/6 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
2.9%
1/34 • Number of events 1 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
|
Hepatobiliary disorders
Hyperbilirubinaemia
|
0.00%
0/4 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/13 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/14 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/4 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/12 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/7 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/7 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/8 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/6 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
2.9%
1/34 • Number of events 1 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
|
Hepatobiliary disorders
Jaundice
|
0.00%
0/4 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
7.7%
1/13 • Number of events 1 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/14 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/4 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/12 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/7 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/7 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/8 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/6 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/34 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
|
Infections and infestations
Sepsis
|
0.00%
0/4 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/13 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
7.1%
1/14 • Number of events 1 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/4 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/12 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/7 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/7 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/8 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
16.7%
1/6 • Number of events 1 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
5.9%
2/34 • Number of events 2 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
|
Infections and infestations
COVID-19
|
0.00%
0/4 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
7.7%
1/13 • Number of events 1 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/14 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/4 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/12 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/7 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/7 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/8 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/6 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
2.9%
1/34 • Number of events 1 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
|
Infections and infestations
Septic shock
|
0.00%
0/4 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/13 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/14 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/4 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/12 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/7 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/7 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/8 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/6 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
5.9%
2/34 • Number of events 2 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
|
Infections and infestations
Escherichia sepsis
|
0.00%
0/4 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/13 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/14 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/4 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/12 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/7 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/7 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/8 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/6 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
2.9%
1/34 • Number of events 1 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
|
Infections and infestations
Fungal infection
|
0.00%
0/4 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/13 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/14 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/4 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/12 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/7 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/7 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/8 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/6 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
2.9%
1/34 • Number of events 1 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
|
Infections and infestations
Infection
|
0.00%
0/4 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/13 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/14 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/4 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/12 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/7 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/7 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/8 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/6 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
2.9%
1/34 • Number of events 1 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
|
Infections and infestations
Influenza
|
0.00%
0/4 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
7.7%
1/13 • Number of events 1 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/14 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/4 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/12 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/7 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/7 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/8 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/6 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/34 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
|
Infections and infestations
Upper respiratory tract infection
|
0.00%
0/4 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/13 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/14 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/4 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/12 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/7 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/7 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/8 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/6 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
2.9%
1/34 • Number of events 1 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
|
Metabolism and nutrition disorders
Hypercalcaemia
|
0.00%
0/4 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/13 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/14 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/4 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/12 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/7 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/7 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/8 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/6 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
2.9%
1/34 • Number of events 1 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
|
Metabolism and nutrition disorders
Hyponatraemia
|
0.00%
0/4 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/13 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/14 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/4 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/12 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/7 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/7 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/8 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/6 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
2.9%
1/34 • Number of events 1 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
|
Musculoskeletal and connective tissue disorders
Back pain
|
0.00%
0/4 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/13 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
14.3%
2/14 • Number of events 2 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/4 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/12 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/7 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/7 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/8 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/6 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
2.9%
1/34 • Number of events 1 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
|
Vascular disorders
Shock
|
0.00%
0/4 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/13 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/14 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/4 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/12 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/7 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/7 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/8 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/6 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
2.9%
1/34 • Number of events 1 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
|
Musculoskeletal and connective tissue disorders
Flank pain
|
0.00%
0/4 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/13 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/14 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/4 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/12 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/7 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/7 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/8 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/6 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
2.9%
1/34 • Number of events 1 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
|
Musculoskeletal and connective tissue disorders
Neck pain
|
0.00%
0/4 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/13 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/14 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/4 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/12 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/7 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/7 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/8 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/6 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
2.9%
1/34 • Number of events 1 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Breast cancer
|
0.00%
0/4 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/13 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/14 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/4 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/12 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/7 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/7 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/8 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/6 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
2.9%
1/34 • Number of events 1 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Cancer pain
|
0.00%
0/4 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/13 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/14 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/4 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/12 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/7 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/7 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/8 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
16.7%
1/6 • Number of events 1 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/34 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Tumour pain
|
0.00%
0/4 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/13 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/14 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/4 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/12 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/7 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/7 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/8 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/6 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
2.9%
1/34 • Number of events 2 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
|
Nervous system disorders
Apraxia
|
0.00%
0/4 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/13 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
7.1%
1/14 • Number of events 1 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/4 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/12 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/7 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/7 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/8 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/6 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/34 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
|
Nervous system disorders
Headache
|
0.00%
0/4 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/13 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/14 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/4 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/12 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/7 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/7 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/8 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/6 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
2.9%
1/34 • Number of events 1 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
|
Nervous system disorders
Presyncope
|
0.00%
0/4 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/13 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/14 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/4 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/12 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/7 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/7 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/8 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/6 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
2.9%
1/34 • Number of events 1 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
|
Nervous system disorders
Sciatica
|
0.00%
0/4 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/13 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/14 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/4 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/12 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/7 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/7 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/8 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/6 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
2.9%
1/34 • Number of events 1 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
|
Psychiatric disorders
Mental status changes
|
0.00%
0/4 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/13 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/14 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/4 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/12 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/7 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/7 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/8 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/6 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
2.9%
1/34 • Number of events 1 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
|
Renal and urinary disorders
Urinary tract obstruction
|
0.00%
0/4 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/13 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/14 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/4 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/12 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/7 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/7 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/8 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/6 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
2.9%
1/34 • Number of events 1 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
|
Reproductive system and breast disorders
Vaginal haemorrhage
|
0.00%
0/4 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/13 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/14 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/4 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/12 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/7 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/7 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/8 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/6 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
2.9%
1/34 • Number of events 1 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
|
Respiratory, thoracic and mediastinal disorders
Hypoxia
|
0.00%
0/4 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
7.7%
1/13 • Number of events 3 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/14 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/4 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/12 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/7 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/7 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/8 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
16.7%
1/6 • Number of events 1 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
5.9%
2/34 • Number of events 2 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
|
Respiratory, thoracic and mediastinal disorders
Acute respiratory distress syndrome
|
0.00%
0/4 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/13 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/14 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/4 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/12 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/7 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/7 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/8 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
16.7%
1/6 • Number of events 1 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/34 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
|
Respiratory, thoracic and mediastinal disorders
Acute respiratory failure
|
0.00%
0/4 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/13 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/14 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/4 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/12 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/7 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/7 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/8 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/6 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
2.9%
1/34 • Number of events 1 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
|
Respiratory, thoracic and mediastinal disorders
Chronic obstructive pulmonary disease
|
0.00%
0/4 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/13 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/14 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/4 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/12 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/7 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/7 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/8 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/6 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
2.9%
1/34 • Number of events 1 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
|
Respiratory, thoracic and mediastinal disorders
Malignant airway obstruction
|
0.00%
0/4 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/13 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/14 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/4 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/12 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/7 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/7 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/8 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/6 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
2.9%
1/34 • Number of events 1 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
|
Skin and subcutaneous tissue disorders
Rash maculo-papular
|
0.00%
0/4 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/13 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/14 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/4 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/12 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/7 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/7 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/8 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
16.7%
1/6 • Number of events 1 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
11.8%
4/34 • Number of events 4 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
|
Skin and subcutaneous tissue disorders
Erythema multiforme
|
0.00%
0/4 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/13 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/14 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/4 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/12 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/7 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/7 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/8 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
16.7%
1/6 • Number of events 1 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/34 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
|
Skin and subcutaneous tissue disorders
Rash macular
|
0.00%
0/4 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/13 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/14 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/4 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/12 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/7 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/7 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/8 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/6 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
2.9%
1/34 • Number of events 1 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
|
Vascular disorders
Hypotension
|
0.00%
0/4 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/13 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/14 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/4 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/12 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/7 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/7 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/8 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/6 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
8.8%
3/34 • Number of events 3 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
|
Vascular disorders
Peripheral arterial occlusive disease
|
0.00%
0/4 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/13 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/14 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/4 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/12 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/7 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/7 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/8 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
16.7%
1/6 • Number of events 1 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/34 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
Other adverse events
| Measure |
Phase 1a: Brimarafenib 60 mg
n=4 participants at risk
Participants received brimarafenib 60 mg orally on Day 1 and then daily from Day 4 onwards. Participants continued treatment until disease progression, unacceptable toxicity, or study completion.
|
Phase 1b: Group 1 (Brimarafenib 25 mg)
n=13 participants at risk
Participants with solid tumors harboring BRAF V600 mutations (excluding colorectal cancer \[CRC\]) who had progressed on prior BRAF and/or MEK (mitogen-activated protein kinase) inhibition were randomized using Interactive Response Technology (IRT) to receive 25 mg of brimarafenib once daily. Participants continued treatment until disease progression, unacceptable toxicity, or study completion.
|
Phase 1b: Group 1 (Brimarafenib 40 mg Randomized)
n=14 participants at risk
Participants with solid tumors harboring BRAF V600 mutations (excluding CRC) who had progressed on prior BRAF and/or MEK inhibition were randomized using IRT to receive 40 mg of brimarafenib once daily. Participants continued treatment until disease progression, unacceptable toxicity, or study completion.
|
Phase 1a: Brimarafenib 5 mg
n=4 participants at risk
Participants received brimarafenib 5 mg orally on Day 1 and then daily from Day 4 onwards. Participants continued treatment until disease progression, unacceptable toxicity, or study completion.
|
Phase 1a: Brimarafenib 10 mg
n=12 participants at risk
Participants received brimarafenib 10 mg orally on Day 1 and then daily from Day 4 onwards. Participants continued treatment until disease progression, unacceptable toxicity, or study completion.
|
Phase 1a: Brimarafenib 15 mg
n=7 participants at risk
Participants received brimarafenib 15 mg orally on Day 1 and then daily from Day 4 onwards. Participants continued treatment until disease progression, unacceptable toxicity, or study completion.
|
Phase 1a: Brimarafenib 25 mg
n=7 participants at risk
Participants received brimarafenib 25 mg orally on Day 1 and then daily from Day 4 onwards. Participants continued treatment until disease progression, unacceptable toxicity, or study completion.
|
Phase 1a: Brimarafenib 40 mg
n=8 participants at risk
Participants received brimarafenib 40 mg orally on Day 1 and then daily from Day 4 onwards. Participants continued treatment until disease progression, unacceptable toxicity, or study completion.
|
Phase 1b: Group 1 (Brimarafenib 40 mg Non-Randomized)
n=6 participants at risk
Participants with solid tumors harboring BRAF V600 mutations (excluding CRC) enrolled under Protocol Version 4.0 were treated with 40 mg of brimarafenib once daily without randomization. Participants continued treatment until disease progression, unacceptable toxicity, or study completion.
|
Phase 1b: Group 2 (Brimarafenib 40 mg)
n=34 participants at risk
Participants with advanced solid tumors harboring Class II mutations or a BRAF fusion mutation were treated with 40 mg of brimarafenib once daily. Participants continued treatment until disease progression, unacceptable toxicity, or study completion.
|
|---|---|---|---|---|---|---|---|---|---|---|
|
Investigations
Aspartate aminotransferase increased
|
50.0%
2/4 • Number of events 4 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
15.4%
2/13 • Number of events 2 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/14 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
25.0%
1/4 • Number of events 1 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
25.0%
3/12 • Number of events 3 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
14.3%
1/7 • Number of events 1 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
14.3%
1/7 • Number of events 1 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
37.5%
3/8 • Number of events 3 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
16.7%
1/6 • Number of events 2 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
29.4%
10/34 • Number of events 15 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
|
General disorders
Fatigue
|
25.0%
1/4 • Number of events 1 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
23.1%
3/13 • Number of events 3 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
7.1%
1/14 • Number of events 2 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/4 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
41.7%
5/12 • Number of events 5 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
14.3%
1/7 • Number of events 1 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
14.3%
1/7 • Number of events 1 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
25.0%
2/8 • Number of events 2 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
16.7%
1/6 • Number of events 1 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
23.5%
8/34 • Number of events 12 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
|
General disorders
Pyrexia
|
25.0%
1/4 • Number of events 1 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
7.7%
1/13 • Number of events 1 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
7.1%
1/14 • Number of events 1 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/4 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
8.3%
1/12 • Number of events 1 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/7 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
14.3%
1/7 • Number of events 1 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
12.5%
1/8 • Number of events 1 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
16.7%
1/6 • Number of events 1 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
17.6%
6/34 • Number of events 7 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
|
Eye disorders
Dry eye
|
0.00%
0/4 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
7.7%
1/13 • Number of events 1 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/14 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/4 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
16.7%
2/12 • Number of events 2 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
14.3%
1/7 • Number of events 1 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/7 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
12.5%
1/8 • Number of events 1 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
16.7%
1/6 • Number of events 1 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
5.9%
2/34 • Number of events 2 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
|
Eye disorders
Cataract
|
0.00%
0/4 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/13 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/14 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/4 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/12 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
14.3%
1/7 • Number of events 1 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/7 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/8 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/6 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/34 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
|
Investigations
Alanine aminotransferase increased
|
25.0%
1/4 • Number of events 1 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
15.4%
2/13 • Number of events 2 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/14 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
25.0%
1/4 • Number of events 2 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
25.0%
3/12 • Number of events 3 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
14.3%
1/7 • Number of events 1 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
28.6%
2/7 • Number of events 2 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
37.5%
3/8 • Number of events 3 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
16.7%
1/6 • Number of events 2 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
29.4%
10/34 • Number of events 14 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
|
Investigations
Platelet count decreased
|
25.0%
1/4 • Number of events 2 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/13 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
7.1%
1/14 • Number of events 1 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/4 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
16.7%
2/12 • Number of events 2 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
14.3%
1/7 • Number of events 1 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
28.6%
2/7 • Number of events 2 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
12.5%
1/8 • Number of events 1 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
33.3%
2/6 • Number of events 3 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
14.7%
5/34 • Number of events 8 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
|
Investigations
Blood creatinine increased
|
75.0%
3/4 • Number of events 3 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
7.7%
1/13 • Number of events 2 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
7.1%
1/14 • Number of events 1 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/4 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
8.3%
1/12 • Number of events 1 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
28.6%
2/7 • Number of events 2 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/7 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
12.5%
1/8 • Number of events 1 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/6 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
14.7%
5/34 • Number of events 8 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
|
Investigations
Blood alkaline phosphatase increased
|
50.0%
2/4 • Number of events 2 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
7.7%
1/13 • Number of events 1 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/14 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/4 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/12 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
28.6%
2/7 • Number of events 2 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
28.6%
2/7 • Number of events 2 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/8 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
16.7%
1/6 • Number of events 1 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
2.9%
1/34 • Number of events 2 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
|
Investigations
Blood creatine phosphokinase increased
|
50.0%
2/4 • Number of events 10 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/13 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
21.4%
3/14 • Number of events 4 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/4 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/12 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/7 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
14.3%
1/7 • Number of events 1 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
12.5%
1/8 • Number of events 1 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/6 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
20.6%
7/34 • Number of events 13 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
|
Investigations
Neutrophil count decreased
|
50.0%
2/4 • Number of events 2 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/13 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
7.1%
1/14 • Number of events 1 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/4 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
8.3%
1/12 • Number of events 2 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
14.3%
1/7 • Number of events 2 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/7 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/8 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/6 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
5.9%
2/34 • Number of events 2 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
|
Investigations
Lymphocyte count decreased
|
25.0%
1/4 • Number of events 1 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/13 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/14 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/4 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
8.3%
1/12 • Number of events 1 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
14.3%
1/7 • Number of events 2 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/7 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/8 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/6 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
2.9%
1/34 • Number of events 2 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
|
Investigations
White blood cell count decreased
|
25.0%
1/4 • Number of events 2 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/13 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
7.1%
1/14 • Number of events 1 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/4 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/12 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
14.3%
1/7 • Number of events 2 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/7 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/8 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/6 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
8.8%
3/34 • Number of events 3 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
|
Investigations
Electrocardiogram QT prolonged
|
25.0%
1/4 • Number of events 1 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/13 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
7.1%
1/14 • Number of events 1 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/4 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/12 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
14.3%
1/7 • Number of events 2 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/7 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/8 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/6 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/34 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
|
Investigations
Activated partial thromboplastin time prolonged
|
25.0%
1/4 • Number of events 1 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/13 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/14 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/4 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/12 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/7 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/7 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
12.5%
1/8 • Number of events 1 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/6 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/34 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
|
Investigations
Blood bilirubin increased
|
0.00%
0/4 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
7.7%
1/13 • Number of events 1 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/14 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/4 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/12 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
14.3%
1/7 • Number of events 1 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/7 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
12.5%
1/8 • Number of events 1 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/6 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
2.9%
1/34 • Number of events 1 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
|
Investigations
International normalised ratio increased
|
0.00%
0/4 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/13 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/14 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/4 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/12 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/7 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
14.3%
1/7 • Number of events 1 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
12.5%
1/8 • Number of events 1 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/6 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/34 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
|
Investigations
Weight increased
|
25.0%
1/4 • Number of events 1 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/13 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/14 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/4 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/12 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
14.3%
1/7 • Number of events 1 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/7 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/8 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/6 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/34 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
|
Investigations
Blood bilirubin decreased
|
0.00%
0/4 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/13 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/14 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/4 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/12 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/7 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
14.3%
1/7 • Number of events 1 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/8 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/6 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/34 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
|
Investigations
Blood lactate dehydrogenase increased
|
0.00%
0/4 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/13 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/14 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/4 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/12 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
14.3%
1/7 • Number of events 1 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/7 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/8 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/6 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/34 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
|
Investigations
Blood thyroid stimulating hormone increased
|
0.00%
0/4 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/13 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/14 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/4 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
8.3%
1/12 • Number of events 1 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/7 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/7 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/8 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/6 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/34 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
|
Investigations
Blood urea increased
|
25.0%
1/4 • Number of events 1 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/13 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/14 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/4 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/12 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/7 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/7 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/8 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/6 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/34 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
|
Investigations
Ejection fraction decreased
|
0.00%
0/4 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/13 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/14 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/4 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/12 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/7 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/7 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
12.5%
1/8 • Number of events 1 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/6 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/34 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
|
Investigations
Weight decreased
|
0.00%
0/4 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
7.7%
1/13 • Number of events 1 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
7.1%
1/14 • Number of events 1 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/4 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/12 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
14.3%
1/7 • Number of events 1 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/7 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/8 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/6 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
5.9%
2/34 • Number of events 2 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
|
Investigations
White blood cell count increased
|
0.00%
0/4 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/13 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/14 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/4 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
8.3%
1/12 • Number of events 1 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/7 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/7 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/8 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/6 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/34 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
|
Skin and subcutaneous tissue disorders
Dermatitis acneiform
|
50.0%
2/4 • Number of events 6 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
30.8%
4/13 • Number of events 4 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
50.0%
7/14 • Number of events 11 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
25.0%
1/4 • Number of events 1 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
50.0%
6/12 • Number of events 6 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
85.7%
6/7 • Number of events 6 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
28.6%
2/7 • Number of events 2 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
50.0%
4/8 • Number of events 4 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
50.0%
3/6 • Number of events 3 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
23.5%
8/34 • Number of events 12 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
|
Skin and subcutaneous tissue disorders
Rash maculo-papular
|
0.00%
0/4 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
7.7%
1/13 • Number of events 1 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
35.7%
5/14 • Number of events 6 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/4 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
50.0%
6/12 • Number of events 6 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
14.3%
1/7 • Number of events 1 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
42.9%
3/7 • Number of events 4 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
37.5%
3/8 • Number of events 4 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
33.3%
2/6 • Number of events 2 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
20.6%
7/34 • Number of events 12 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
|
Skin and subcutaneous tissue disorders
Pruritus
|
25.0%
1/4 • Number of events 1 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/13 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
7.1%
1/14 • Number of events 1 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/4 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
33.3%
4/12 • Number of events 4 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/7 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
14.3%
1/7 • Number of events 1 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
25.0%
2/8 • Number of events 2 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/6 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
11.8%
4/34 • Number of events 4 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
|
Skin and subcutaneous tissue disorders
Rash
|
0.00%
0/4 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
15.4%
2/13 • Number of events 5 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
21.4%
3/14 • Number of events 3 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/4 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/12 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/7 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
14.3%
1/7 • Number of events 1 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
12.5%
1/8 • Number of events 2 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
16.7%
1/6 • Number of events 1 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
17.6%
6/34 • Number of events 6 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
|
Skin and subcutaneous tissue disorders
Palmar-plantar erythrodysaesthesia syndrome
|
25.0%
1/4 • Number of events 1 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/13 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/14 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/4 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/12 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
14.3%
1/7 • Number of events 1 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/7 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/8 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/6 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/34 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
|
Skin and subcutaneous tissue disorders
Acne
|
0.00%
0/4 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/13 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/14 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/4 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
8.3%
1/12 • Number of events 1 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/7 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/7 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/8 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/6 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
2.9%
1/34 • Number of events 1 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
|
Skin and subcutaneous tissue disorders
Actinic keratosis
|
0.00%
0/4 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/13 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/14 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/4 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
8.3%
1/12 • Number of events 1 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/7 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/7 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/8 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/6 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/34 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
|
Skin and subcutaneous tissue disorders
Alopecia
|
0.00%
0/4 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/13 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/14 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/4 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/12 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
14.3%
1/7 • Number of events 1 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/7 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/8 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/6 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
2.9%
1/34 • Number of events 1 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
|
Skin and subcutaneous tissue disorders
Dermatitis contact
|
25.0%
1/4 • Number of events 1 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/13 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/14 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/4 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/12 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/7 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/7 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/8 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/6 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/34 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
|
Skin and subcutaneous tissue disorders
Dry skin
|
0.00%
0/4 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/13 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
7.1%
1/14 • Number of events 1 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/4 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/12 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/7 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/7 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
12.5%
1/8 • Number of events 1 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/6 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
8.8%
3/34 • Number of events 3 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
|
Skin and subcutaneous tissue disorders
Erythema
|
0.00%
0/4 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/13 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/14 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/4 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
8.3%
1/12 • Number of events 1 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/7 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/7 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/8 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/6 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
2.9%
1/34 • Number of events 4 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
|
Skin and subcutaneous tissue disorders
Erythema multiforme
|
0.00%
0/4 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/13 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/14 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/4 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
8.3%
1/12 • Number of events 1 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/7 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/7 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/8 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/6 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/34 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
|
Skin and subcutaneous tissue disorders
Hair growth abnormal
|
0.00%
0/4 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/13 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/14 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/4 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
8.3%
1/12 • Number of events 1 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/7 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/7 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/8 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/6 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/34 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
|
Skin and subcutaneous tissue disorders
Hyperkeratosis
|
25.0%
1/4 • Number of events 1 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/13 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/14 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/4 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/12 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/7 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/7 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/8 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/6 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/34 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
|
Skin and subcutaneous tissue disorders
Koilonychia
|
0.00%
0/4 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/13 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/14 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/4 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/12 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/7 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/7 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
12.5%
1/8 • Number of events 1 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/6 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/34 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
|
Skin and subcutaneous tissue disorders
Nail disorder
|
0.00%
0/4 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/13 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/14 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/4 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/12 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/7 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/7 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
12.5%
1/8 • Number of events 1 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/6 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
2.9%
1/34 • Number of events 1 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
|
Skin and subcutaneous tissue disorders
Night sweats
|
0.00%
0/4 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/13 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/14 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/4 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
8.3%
1/12 • Number of events 1 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/7 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/7 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/8 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/6 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/34 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
|
Skin and subcutaneous tissue disorders
Rash macular
|
0.00%
0/4 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/13 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/14 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/4 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
8.3%
1/12 • Number of events 1 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/7 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/7 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/8 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/6 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
5.9%
2/34 • Number of events 2 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
|
Skin and subcutaneous tissue disorders
Rash papular
|
0.00%
0/4 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/13 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/14 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/4 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/12 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/7 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
14.3%
1/7 • Number of events 1 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/8 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/6 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
2.9%
1/34 • Number of events 1 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
|
Skin and subcutaneous tissue disorders
Rash pruritic
|
0.00%
0/4 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/13 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/14 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/4 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/12 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/7 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/7 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
12.5%
1/8 • Number of events 1 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/6 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/34 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
|
Skin and subcutaneous tissue disorders
Skin disorder
|
0.00%
0/4 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
7.7%
1/13 • Number of events 1 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/14 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/4 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/12 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
14.3%
1/7 • Number of events 1 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/7 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/8 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/6 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/34 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
|
Skin and subcutaneous tissue disorders
Skin fissures
|
0.00%
0/4 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/13 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/14 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/4 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
8.3%
1/12 • Number of events 1 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/7 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/7 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/8 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/6 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/34 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
|
Skin and subcutaneous tissue disorders
Skin hypopigmentation
|
0.00%
0/4 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/13 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/14 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/4 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
8.3%
1/12 • Number of events 1 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/7 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/7 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/8 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/6 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/34 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
|
Skin and subcutaneous tissue disorders
Skin lesion
|
0.00%
0/4 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/13 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/14 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/4 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
8.3%
1/12 • Number of events 1 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/7 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/7 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/8 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/6 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/34 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
|
Skin and subcutaneous tissue disorders
Urticaria
|
0.00%
0/4 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/13 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/14 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/4 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/12 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/7 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
14.3%
1/7 • Number of events 1 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/8 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
16.7%
1/6 • Number of events 2 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/34 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
|
Skin and subcutaneous tissue disorders
Vasculitic rash
|
25.0%
1/4 • Number of events 1 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/13 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/14 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/4 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/12 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/7 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/7 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/8 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/6 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/34 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
|
Gastrointestinal disorders
Nausea
|
0.00%
0/4 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
15.4%
2/13 • Number of events 2 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
21.4%
3/14 • Number of events 4 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/4 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
25.0%
3/12 • Number of events 3 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
71.4%
5/7 • Number of events 6 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
14.3%
1/7 • Number of events 1 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
37.5%
3/8 • Number of events 4 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
16.7%
1/6 • Number of events 1 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
32.4%
11/34 • Number of events 12 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
|
Gastrointestinal disorders
Diarrhoea
|
0.00%
0/4 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/13 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/14 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
25.0%
1/4 • Number of events 1 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
16.7%
2/12 • Number of events 2 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
57.1%
4/7 • Number of events 7 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
28.6%
2/7 • Number of events 2 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
25.0%
2/8 • Number of events 2 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/6 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
2.9%
1/34 • Number of events 1 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
|
Gastrointestinal disorders
Abdominal pain
|
0.00%
0/4 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/13 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/14 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
25.0%
1/4 • Number of events 1 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
8.3%
1/12 • Number of events 1 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
28.6%
2/7 • Number of events 3 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
14.3%
1/7 • Number of events 1 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
37.5%
3/8 • Number of events 3 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/6 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
8.8%
3/34 • Number of events 3 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
|
Gastrointestinal disorders
Constipation
|
25.0%
1/4 • Number of events 1 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
23.1%
3/13 • Number of events 3 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
7.1%
1/14 • Number of events 1 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/4 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
16.7%
2/12 • Number of events 2 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
14.3%
1/7 • Number of events 1 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
14.3%
1/7 • Number of events 2 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
12.5%
1/8 • Number of events 1 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
50.0%
3/6 • Number of events 3 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
23.5%
8/34 • Number of events 9 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
|
Gastrointestinal disorders
Abdominal distension
|
0.00%
0/4 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/13 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
7.1%
1/14 • Number of events 1 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/4 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
8.3%
1/12 • Number of events 1 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/7 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
28.6%
2/7 • Number of events 2 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
12.5%
1/8 • Number of events 1 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/6 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
2.9%
1/34 • Number of events 1 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
|
Gastrointestinal disorders
Dry mouth
|
0.00%
0/4 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
7.7%
1/13 • Number of events 1 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
14.3%
2/14 • Number of events 2 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/4 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
16.7%
2/12 • Number of events 2 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/7 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/7 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
12.5%
1/8 • Number of events 1 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
16.7%
1/6 • Number of events 1 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
11.8%
4/34 • Number of events 4 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
|
Gastrointestinal disorders
Stomatitis
|
50.0%
2/4 • Number of events 2 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/13 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/14 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/4 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/12 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/7 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
14.3%
1/7 • Number of events 1 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/8 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/6 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
5.9%
2/34 • Number of events 2 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
|
Gastrointestinal disorders
Vomiting
|
0.00%
0/4 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
7.7%
1/13 • Number of events 1 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
7.1%
1/14 • Number of events 1 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/4 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/12 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
28.6%
2/7 • Number of events 6 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/7 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/8 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/6 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
17.6%
6/34 • Number of events 9 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
|
Gastrointestinal disorders
Gastrooesophageal reflux disease
|
0.00%
0/4 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/13 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
7.1%
1/14 • Number of events 1 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/4 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/12 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
14.3%
1/7 • Number of events 2 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/7 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
12.5%
1/8 • Number of events 1 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
16.7%
1/6 • Number of events 1 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
11.8%
4/34 • Number of events 4 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
|
Gastrointestinal disorders
Anal fissure
|
0.00%
0/4 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/13 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/14 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/4 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
8.3%
1/12 • Number of events 1 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/7 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/7 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/8 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/6 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/34 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
|
Gastrointestinal disorders
Ascites
|
0.00%
0/4 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/13 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/14 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/4 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/12 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/7 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
14.3%
1/7 • Number of events 1 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/8 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/6 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
2.9%
1/34 • Number of events 2 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
|
Gastrointestinal disorders
Colitis
|
0.00%
0/4 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/13 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/14 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/4 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
8.3%
1/12 • Number of events 1 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/7 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/7 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/8 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/6 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/34 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
|
Gastrointestinal disorders
Flatulence
|
0.00%
0/4 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/13 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/14 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/4 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
8.3%
1/12 • Number of events 1 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/7 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/7 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/8 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/6 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/34 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
|
Gastrointestinal disorders
Gastric ulcer
|
0.00%
0/4 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/13 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/14 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/4 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/12 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/7 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/7 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
12.5%
1/8 • Number of events 1 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/6 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/34 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
|
Gastrointestinal disorders
Glossitis
|
0.00%
0/4 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/13 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/14 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/4 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/12 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/7 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/7 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
12.5%
1/8 • Number of events 1 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/6 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/34 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
|
Gastrointestinal disorders
Haemorrhoids
|
0.00%
0/4 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/13 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/14 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/4 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
8.3%
1/12 • Number of events 1 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/7 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/7 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/8 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/6 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/34 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
|
Gastrointestinal disorders
Odynophagia
|
0.00%
0/4 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/13 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/14 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/4 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/12 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/7 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/7 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
12.5%
1/8 • Number of events 1 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/6 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/34 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
|
Gastrointestinal disorders
Toothache
|
0.00%
0/4 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/13 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/14 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/4 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/12 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
14.3%
1/7 • Number of events 1 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/7 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/8 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/6 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/34 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
|
Metabolism and nutrition disorders
Hypophosphataemia
|
0.00%
0/4 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/13 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/14 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
25.0%
1/4 • Number of events 1 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
25.0%
3/12 • Number of events 4 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
14.3%
1/7 • Number of events 1 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
14.3%
1/7 • Number of events 1 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
12.5%
1/8 • Number of events 1 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
16.7%
1/6 • Number of events 3 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
14.7%
5/34 • Number of events 5 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
|
Metabolism and nutrition disorders
Hypokalaemia
|
0.00%
0/4 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
7.7%
1/13 • Number of events 1 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/14 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/4 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
16.7%
2/12 • Number of events 2 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
28.6%
2/7 • Number of events 2 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
14.3%
1/7 • Number of events 1 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
12.5%
1/8 • Number of events 1 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
33.3%
2/6 • Number of events 3 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
14.7%
5/34 • Number of events 5 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
|
Metabolism and nutrition disorders
Hyponatraemia
|
25.0%
1/4 • Number of events 1 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/13 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/14 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/4 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
16.7%
2/12 • Number of events 2 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
14.3%
1/7 • Number of events 1 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
14.3%
1/7 • Number of events 1 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/8 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
16.7%
1/6 • Number of events 1 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
11.8%
4/34 • Number of events 4 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
|
Metabolism and nutrition disorders
Hypocalcaemia
|
50.0%
2/4 • Number of events 3 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/13 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/14 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/4 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/12 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/7 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
14.3%
1/7 • Number of events 1 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
12.5%
1/8 • Number of events 1 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
16.7%
1/6 • Number of events 1 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
8.8%
3/34 • Number of events 4 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
|
Metabolism and nutrition disorders
Hypoalbuminaemia
|
25.0%
1/4 • Number of events 3 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/13 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/14 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/4 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
16.7%
2/12 • Number of events 2 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/7 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/7 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/8 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
16.7%
1/6 • Number of events 1 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
8.8%
3/34 • Number of events 5 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
|
Metabolism and nutrition disorders
Hypomagnesaemia
|
0.00%
0/4 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/13 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/14 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/4 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/12 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
14.3%
1/7 • Number of events 1 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
14.3%
1/7 • Number of events 1 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
12.5%
1/8 • Number of events 1 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
16.7%
1/6 • Number of events 1 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/34 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
|
Metabolism and nutrition disorders
Decreased appetite
|
0.00%
0/4 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/13 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/14 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/4 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
16.7%
2/12 • Number of events 2 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/7 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/7 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/8 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/6 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
14.7%
5/34 • Number of events 5 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
|
Metabolism and nutrition disorders
Hyperglycaemia
|
25.0%
1/4 • Number of events 1 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
7.7%
1/13 • Number of events 1 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/14 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/4 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/12 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
14.3%
1/7 • Number of events 1 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/7 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/8 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/6 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
2.9%
1/34 • Number of events 1 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
|
Metabolism and nutrition disorders
Hyperkalaemia
|
0.00%
0/4 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/13 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/14 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/4 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/12 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/7 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
14.3%
1/7 • Number of events 1 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/8 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/6 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/34 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
|
Metabolism and nutrition disorders
Iron deficiency
|
0.00%
0/4 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/13 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/14 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
25.0%
1/4 • Number of events 1 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/12 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/7 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/7 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/8 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/6 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/34 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
|
Metabolism and nutrition disorders
Vitamin D deficiency
|
0.00%
0/4 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/13 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/14 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/4 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/12 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
14.3%
1/7 • Number of events 1 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/7 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/8 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/6 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
2.9%
1/34 • Number of events 1 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
|
Infections and infestations
Paronychia
|
50.0%
2/4 • Number of events 2 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/13 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/14 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/4 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
16.7%
2/12 • Number of events 6 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
14.3%
1/7 • Number of events 1 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
14.3%
1/7 • Number of events 1 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
12.5%
1/8 • Number of events 1 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
16.7%
1/6 • Number of events 1 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
5.9%
2/34 • Number of events 2 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
|
Infections and infestations
COVID-19
|
25.0%
1/4 • Number of events 1 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
23.1%
3/13 • Number of events 4 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/14 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/4 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
8.3%
1/12 • Number of events 2 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
28.6%
2/7 • Number of events 2 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
14.3%
1/7 • Number of events 1 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
12.5%
1/8 • Number of events 1 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/6 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
8.8%
3/34 • Number of events 3 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
|
Infections and infestations
Pneumonia
|
0.00%
0/4 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/13 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/14 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/4 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
25.0%
3/12 • Number of events 3 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/7 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/7 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/8 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/6 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
2.9%
1/34 • Number of events 1 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
|
Infections and infestations
Localised infection
|
0.00%
0/4 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/13 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/14 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/4 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
8.3%
1/12 • Number of events 3 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/7 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
14.3%
1/7 • Number of events 1 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/8 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/6 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
2.9%
1/34 • Number of events 1 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
|
Infections and infestations
Urinary tract infection
|
0.00%
0/4 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/13 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/14 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/4 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/12 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
14.3%
1/7 • Number of events 3 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/7 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/8 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/6 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
8.8%
3/34 • Number of events 3 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
|
Infections and infestations
Body tinea
|
0.00%
0/4 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/13 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/14 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/4 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/12 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/7 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
14.3%
1/7 • Number of events 1 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/8 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/6 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/34 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
|
Infections and infestations
Clostridium difficile colitis
|
0.00%
0/4 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/13 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/14 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/4 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/12 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
14.3%
1/7 • Number of events 1 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/7 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/8 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/6 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/34 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
|
Infections and infestations
Fungal skin infection
|
0.00%
0/4 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/13 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/14 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/4 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/12 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/7 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/7 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
12.5%
1/8 • Number of events 1 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/6 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/34 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
|
Infections and infestations
Herpes zoster
|
0.00%
0/4 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/13 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/14 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/4 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
8.3%
1/12 • Number of events 1 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/7 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/7 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/8 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
16.7%
1/6 • Number of events 1 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/34 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
|
Infections and infestations
Hordeolum
|
0.00%
0/4 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/13 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/14 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/4 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
8.3%
1/12 • Number of events 1 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/7 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/7 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/8 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/6 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/34 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
|
Infections and infestations
Oral candidiasis
|
0.00%
0/4 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/13 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
7.1%
1/14 • Number of events 1 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/4 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
8.3%
1/12 • Number of events 1 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/7 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/7 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/8 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/6 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
2.9%
1/34 • Number of events 1 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
|
Infections and infestations
Skin infection
|
0.00%
0/4 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/13 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/14 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/4 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/12 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/7 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/7 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
12.5%
1/8 • Number of events 1 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/6 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
2.9%
1/34 • Number of events 2 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
|
Infections and infestations
Tinea pedis
|
0.00%
0/4 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/13 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/14 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/4 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/12 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/7 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/7 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
12.5%
1/8 • Number of events 1 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/6 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/34 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
|
Infections and infestations
Upper respiratory tract infection
|
0.00%
0/4 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
7.7%
1/13 • Number of events 1 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
7.1%
1/14 • Number of events 1 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/4 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/12 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
14.3%
1/7 • Number of events 1 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/7 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/8 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/6 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
2.9%
1/34 • Number of events 1 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
|
Infections and infestations
Wound infection
|
0.00%
0/4 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/13 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/14 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/4 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
8.3%
1/12 • Number of events 1 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/7 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/7 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/8 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/6 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
2.9%
1/34 • Number of events 1 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
|
Musculoskeletal and connective tissue disorders
Arthralgia
|
25.0%
1/4 • Number of events 1 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/13 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
14.3%
2/14 • Number of events 2 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/4 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
25.0%
3/12 • Number of events 3 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/7 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/7 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
12.5%
1/8 • Number of events 2 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
16.7%
1/6 • Number of events 1 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
5.9%
2/34 • Number of events 4 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
|
Musculoskeletal and connective tissue disorders
Myalgia
|
25.0%
1/4 • Number of events 1 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/13 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
14.3%
2/14 • Number of events 2 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/4 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
8.3%
1/12 • Number of events 1 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
14.3%
1/7 • Number of events 1 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/7 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
12.5%
1/8 • Number of events 2 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/6 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
5.9%
2/34 • Number of events 3 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
|
Musculoskeletal and connective tissue disorders
Back pain
|
0.00%
0/4 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/13 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
7.1%
1/14 • Number of events 1 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/4 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/12 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
28.6%
2/7 • Number of events 3 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
14.3%
1/7 • Number of events 1 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/8 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/6 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/34 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
|
Musculoskeletal and connective tissue disorders
Muscle spasms
|
0.00%
0/4 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/13 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
14.3%
2/14 • Number of events 2 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/4 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
8.3%
1/12 • Number of events 1 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
14.3%
1/7 • Number of events 1 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
14.3%
1/7 • Number of events 1 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/8 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
16.7%
1/6 • Number of events 1 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
17.6%
6/34 • Number of events 9 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
|
Musculoskeletal and connective tissue disorders
Neck pain
|
0.00%
0/4 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/13 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/14 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/4 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
8.3%
1/12 • Number of events 1 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
28.6%
2/7 • Number of events 2 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/7 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/8 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/6 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
2.9%
1/34 • Number of events 1 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
|
Musculoskeletal and connective tissue disorders
Pain in extremity
|
25.0%
1/4 • Number of events 2 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
7.7%
1/13 • Number of events 1 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/14 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/4 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/12 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/7 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/7 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
12.5%
1/8 • Number of events 2 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/6 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/34 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
|
Musculoskeletal and connective tissue disorders
Muscular weakness
|
0.00%
0/4 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
7.7%
1/13 • Number of events 1 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/14 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/4 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/12 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
14.3%
1/7 • Number of events 1 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/7 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
12.5%
1/8 • Number of events 1 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/6 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/34 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
|
Musculoskeletal and connective tissue disorders
Rhabdomyolysis
|
25.0%
1/4 • Number of events 4 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/13 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/14 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/4 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/12 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/7 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/7 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/8 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/6 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/34 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
|
Musculoskeletal and connective tissue disorders
Flank pain
|
0.00%
0/4 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/13 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/14 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/4 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
8.3%
1/12 • Number of events 1 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/7 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/7 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/8 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/6 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
2.9%
1/34 • Number of events 1 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
|
Musculoskeletal and connective tissue disorders
Musculoskeletal chest pain
|
0.00%
0/4 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/13 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/14 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/4 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
8.3%
1/12 • Number of events 1 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/7 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/7 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/8 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/6 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/34 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
|
Musculoskeletal and connective tissue disorders
Musculoskeletal discomfort
|
0.00%
0/4 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/13 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/14 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/4 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
8.3%
1/12 • Number of events 1 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/7 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/7 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/8 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/6 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/34 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
|
Musculoskeletal and connective tissue disorders
Osteonecrosis of jaw
|
0.00%
0/4 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/13 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/14 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/4 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
8.3%
1/12 • Number of events 1 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/7 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/7 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/8 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/6 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/34 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
|
Musculoskeletal and connective tissue disorders
Spinal pain
|
0.00%
0/4 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/13 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/14 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/4 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
8.3%
1/12 • Number of events 1 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/7 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/7 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/8 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/6 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/34 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
|
Blood and lymphatic system disorders
Anaemia
|
75.0%
3/4 • Number of events 3 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
7.7%
1/13 • Number of events 2 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
7.1%
1/14 • Number of events 1 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
25.0%
1/4 • Number of events 3 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
16.7%
2/12 • Number of events 2 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
28.6%
2/7 • Number of events 5 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/7 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
37.5%
3/8 • Number of events 3 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/6 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
17.6%
6/34 • Number of events 9 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
|
Blood and lymphatic system disorders
Thrombocytopenia
|
50.0%
2/4 • Number of events 2 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/13 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
7.1%
1/14 • Number of events 1 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/4 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
8.3%
1/12 • Number of events 1 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/7 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
14.3%
1/7 • Number of events 1 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
12.5%
1/8 • Number of events 1 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/6 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
2.9%
1/34 • Number of events 1 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
|
Blood and lymphatic system disorders
Leukopenia
|
0.00%
0/4 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/13 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/14 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/4 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
8.3%
1/12 • Number of events 2 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/7 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/7 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/8 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/6 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/34 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
|
Blood and lymphatic system disorders
Neutropenia
|
0.00%
0/4 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/13 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/14 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/4 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
8.3%
1/12 • Number of events 2 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/7 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/7 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/8 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/6 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
2.9%
1/34 • Number of events 1 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
|
Blood and lymphatic system disorders
Eosinophilia
|
0.00%
0/4 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/13 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/14 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/4 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/12 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/7 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
14.3%
1/7 • Number of events 1 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/8 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/6 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/34 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
|
Blood and lymphatic system disorders
Leukocytosis
|
0.00%
0/4 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/13 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/14 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/4 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
8.3%
1/12 • Number of events 1 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/7 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/7 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/8 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
16.7%
1/6 • Number of events 1 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/34 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
|
General disorders
Peripheral swelling
|
0.00%
0/4 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/13 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/14 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/4 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
16.7%
2/12 • Number of events 2 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
14.3%
1/7 • Number of events 1 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/7 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
12.5%
1/8 • Number of events 1 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/6 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/34 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
|
General disorders
Non-cardiac chest pain
|
0.00%
0/4 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/13 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/14 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/4 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
16.7%
2/12 • Number of events 2 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/7 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/7 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/8 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/6 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
2.9%
1/34 • Number of events 1 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
|
General disorders
Oedema peripheral
|
25.0%
1/4 • Number of events 1 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/13 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
21.4%
3/14 • Number of events 3 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/4 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/12 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/7 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
14.3%
1/7 • Number of events 1 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/8 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
33.3%
2/6 • Number of events 2 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
5.9%
2/34 • Number of events 3 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
|
General disorders
Influenza like illness
|
0.00%
0/4 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
15.4%
2/13 • Number of events 2 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/14 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/4 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/12 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/7 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
14.3%
1/7 • Number of events 1 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/8 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/6 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
2.9%
1/34 • Number of events 1 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
|
General disorders
Mucosal inflammation
|
25.0%
1/4 • Number of events 1 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/13 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/14 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/4 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/12 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/7 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/7 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/8 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/6 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/34 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
|
Respiratory, thoracic and mediastinal disorders
Dyspnoea
|
0.00%
0/4 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
15.4%
2/13 • Number of events 2 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/14 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
25.0%
1/4 • Number of events 1 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
33.3%
4/12 • Number of events 4 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
28.6%
2/7 • Number of events 2 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
14.3%
1/7 • Number of events 1 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
12.5%
1/8 • Number of events 3 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/6 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
11.8%
4/34 • Number of events 5 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
|
Respiratory, thoracic and mediastinal disorders
Cough
|
0.00%
0/4 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
7.7%
1/13 • Number of events 1 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
21.4%
3/14 • Number of events 3 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/4 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
8.3%
1/12 • Number of events 1 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/7 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/7 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
12.5%
1/8 • Number of events 1 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/6 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
8.8%
3/34 • Number of events 4 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
|
Respiratory, thoracic and mediastinal disorders
Nasal congestion
|
0.00%
0/4 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
7.7%
1/13 • Number of events 1 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/14 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/4 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/12 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
14.3%
1/7 • Number of events 1 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/7 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
12.5%
1/8 • Number of events 1 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
16.7%
1/6 • Number of events 1 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/34 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
|
Respiratory, thoracic and mediastinal disorders
Wheezing
|
0.00%
0/4 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/13 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/14 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
25.0%
1/4 • Number of events 1 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/12 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/7 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/7 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
12.5%
1/8 • Number of events 1 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/6 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/34 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
|
Respiratory, thoracic and mediastinal disorders
Dysphonia
|
0.00%
0/4 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/13 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
7.1%
1/14 • Number of events 1 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/4 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/12 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/7 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/7 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
12.5%
1/8 • Number of events 1 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/6 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/34 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
|
Respiratory, thoracic and mediastinal disorders
Epistaxis
|
0.00%
0/4 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/13 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
21.4%
3/14 • Number of events 3 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/4 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
8.3%
1/12 • Number of events 1 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/7 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/7 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/8 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/6 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
2.9%
1/34 • Number of events 1 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
|
Respiratory, thoracic and mediastinal disorders
Pleural effusion
|
0.00%
0/4 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/13 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
7.1%
1/14 • Number of events 1 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/4 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/12 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/7 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
14.3%
1/7 • Number of events 1 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/8 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/6 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
11.8%
4/34 • Number of events 5 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
|
Respiratory, thoracic and mediastinal disorders
Sleep apnoea syndrome
|
0.00%
0/4 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/13 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/14 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/4 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
8.3%
1/12 • Number of events 1 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/7 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/7 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/8 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/6 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/34 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
|
Eye disorders
Vitreous floaters
|
25.0%
1/4 • Number of events 1 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/13 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/14 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/4 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/12 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
14.3%
1/7 • Number of events 1 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/7 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
25.0%
2/8 • Number of events 2 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/6 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/34 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
|
Eye disorders
Vision blurred
|
0.00%
0/4 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/13 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
7.1%
1/14 • Number of events 1 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/4 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/12 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
14.3%
1/7 • Number of events 1 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/7 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
25.0%
2/8 • Number of events 2 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/6 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/34 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
|
Eye disorders
Blepharitis
|
0.00%
0/4 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/13 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/14 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/4 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/12 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/7 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
14.3%
1/7 • Number of events 1 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/8 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/6 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/34 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
|
Eye disorders
Eye pruritus
|
0.00%
0/4 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/13 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/14 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/4 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
8.3%
1/12 • Number of events 1 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/7 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/7 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/8 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/6 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/34 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
|
Eye disorders
Swelling of eyelid
|
25.0%
1/4 • Number of events 1 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/13 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/14 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/4 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/12 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/7 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/7 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/8 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/6 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/34 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
|
Eye disorders
Visual impairment
|
0.00%
0/4 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/13 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/14 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/4 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/12 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/7 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/7 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
12.5%
1/8 • Number of events 1 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/6 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
5.9%
2/34 • Number of events 2 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
|
Nervous system disorders
Headache
|
0.00%
0/4 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
7.7%
1/13 • Number of events 1 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
14.3%
2/14 • Number of events 3 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/4 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
25.0%
3/12 • Number of events 3 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/7 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/7 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
12.5%
1/8 • Number of events 2 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/6 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
2.9%
1/34 • Number of events 3 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
|
Nervous system disorders
Tremor
|
0.00%
0/4 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/13 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
7.1%
1/14 • Number of events 1 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/4 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/12 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/7 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
28.6%
2/7 • Number of events 2 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/8 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/6 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
2.9%
1/34 • Number of events 1 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
|
Nervous system disorders
Amnesia
|
0.00%
0/4 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/13 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/14 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/4 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/12 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
14.3%
1/7 • Number of events 1 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/7 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/8 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/6 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/34 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
|
Nervous system disorders
Dizziness
|
0.00%
0/4 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
15.4%
2/13 • Number of events 2 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/14 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/4 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/12 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/7 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/7 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
12.5%
1/8 • Number of events 1 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/6 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
2.9%
1/34 • Number of events 1 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
|
Nervous system disorders
Hypoaesthesia
|
0.00%
0/4 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/13 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/14 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/4 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/12 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/7 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/7 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
12.5%
1/8 • Number of events 1 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/6 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/34 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
|
Nervous system disorders
Lethargy
|
0.00%
0/4 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/13 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/14 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/4 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/12 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/7 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/7 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
12.5%
1/8 • Number of events 1 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/6 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
8.8%
3/34 • Number of events 3 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
|
Nervous system disorders
Neuralgia
|
0.00%
0/4 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/13 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/14 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/4 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/12 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/7 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/7 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
12.5%
1/8 • Number of events 1 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/6 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
2.9%
1/34 • Number of events 1 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
|
Nervous system disorders
Paraesthesia
|
0.00%
0/4 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/13 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
7.1%
1/14 • Number of events 2 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/4 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/12 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
14.3%
1/7 • Number of events 1 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/7 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/8 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/6 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/34 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
|
Nervous system disorders
Partial seizures
|
0.00%
0/4 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/13 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/14 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/4 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/12 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
14.3%
1/7 • Number of events 1 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/7 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/8 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/6 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/34 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
|
Nervous system disorders
Taste disorder
|
0.00%
0/4 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/13 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/14 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/4 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/12 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/7 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/7 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
12.5%
1/8 • Number of events 1 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/6 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/34 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
|
Vascular disorders
Hypertension
|
25.0%
1/4 • Number of events 1 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/13 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/14 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/4 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/12 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/7 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/7 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
12.5%
1/8 • Number of events 1 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/6 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
8.8%
3/34 • Number of events 3 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
|
Vascular disorders
Brachiocephalic vein thrombosis
|
0.00%
0/4 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/13 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/14 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/4 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/12 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
14.3%
1/7 • Number of events 1 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/7 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/8 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/6 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/34 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
|
Vascular disorders
Hot flush
|
0.00%
0/4 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/13 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/14 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/4 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/12 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
14.3%
1/7 • Number of events 1 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/7 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/8 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/6 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/34 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
|
Vascular disorders
Hypotension
|
0.00%
0/4 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/13 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/14 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/4 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/12 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/7 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/7 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
12.5%
1/8 • Number of events 1 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
16.7%
1/6 • Number of events 1 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/34 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
|
Vascular disorders
Lymphoedema
|
0.00%
0/4 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/13 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/14 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/4 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/12 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/7 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/7 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
12.5%
1/8 • Number of events 1 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/6 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/34 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
|
Vascular disorders
Vena cava thrombosis
|
0.00%
0/4 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/13 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/14 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/4 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/12 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
14.3%
1/7 • Number of events 1 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/7 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/8 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/6 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/34 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
|
Cardiac disorders
Atrial fibrillation
|
25.0%
1/4 • Number of events 1 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
7.7%
1/13 • Number of events 1 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
7.1%
1/14 • Number of events 1 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/4 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/12 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/7 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/7 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
12.5%
1/8 • Number of events 1 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
16.7%
1/6 • Number of events 1 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
14.7%
5/34 • Number of events 5 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
|
Cardiac disorders
Sinus tachycardia
|
0.00%
0/4 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/13 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/14 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/4 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
8.3%
1/12 • Number of events 1 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
14.3%
1/7 • Number of events 1 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/7 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/8 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/6 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/34 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
|
Cardiac disorders
Tachycardia
|
0.00%
0/4 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/13 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/14 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/4 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
8.3%
1/12 • Number of events 1 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/7 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/7 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/8 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/6 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/34 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
|
Cardiac disorders
Ventricular extrasystoles
|
0.00%
0/4 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/13 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/14 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/4 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/12 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/7 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
14.3%
1/7 • Number of events 1 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/8 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/6 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/34 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
|
Psychiatric disorders
Insomnia
|
0.00%
0/4 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
7.7%
1/13 • Number of events 1 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/14 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/4 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
16.7%
2/12 • Number of events 2 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
28.6%
2/7 • Number of events 2 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
14.3%
1/7 • Number of events 1 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/8 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/6 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
2.9%
1/34 • Number of events 1 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
|
Psychiatric disorders
Restlessness
|
0.00%
0/4 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/13 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/14 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/4 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/12 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
14.3%
1/7 • Number of events 1 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/7 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/8 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/6 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/34 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Squamous cell carcinoma
|
0.00%
0/4 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/13 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/14 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/4 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
8.3%
1/12 • Number of events 2 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/7 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/7 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/8 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/6 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/34 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Basal cell carcinoma
|
0.00%
0/4 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/13 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/14 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/4 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
8.3%
1/12 • Number of events 1 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/7 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/7 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/8 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/6 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/34 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
|
Eye disorders
Eye pain
|
—
0/0 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/13 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/14 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
—
0/0 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
—
0/0 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
—
0/0 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
—
0/0 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
—
0/0 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/6 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
2.9%
1/34 • Number of events 1 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Melanocytic naevus
|
0.00%
0/4 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/13 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/14 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/4 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
8.3%
1/12 • Number of events 1 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/7 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/7 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/8 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/6 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/34 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
|
Injury, poisoning and procedural complications
Foot fracture
|
0.00%
0/4 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/13 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/14 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/4 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/12 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/7 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/7 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
12.5%
1/8 • Number of events 2 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/6 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/34 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
|
Injury, poisoning and procedural complications
Procedural pain
|
0.00%
0/4 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/13 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/14 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/4 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
8.3%
1/12 • Number of events 1 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/7 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/7 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/8 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/6 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
2.9%
1/34 • Number of events 1 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
|
Renal and urinary disorders
Dysuria
|
0.00%
0/4 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/13 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/14 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
25.0%
1/4 • Number of events 1 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/12 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/7 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/7 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/8 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/6 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
2.9%
1/34 • Number of events 1 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
|
Renal and urinary disorders
Renal ischaemia
|
25.0%
1/4 • Number of events 1 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/13 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/14 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/4 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/12 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/7 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/7 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/8 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/6 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/34 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
|
Ear and labyrinth disorders
Ear congestion
|
0.00%
0/4 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/13 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/14 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/4 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/12 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
14.3%
1/7 • Number of events 1 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/7 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/8 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/6 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/34 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
|
Immune system disorders
Seasonal allergy
|
0.00%
0/4 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/13 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/14 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/4 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
8.3%
1/12 • Number of events 1 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/7 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/7 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/8 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/6 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/34 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
|
Reproductive system and breast disorders
Vaginal haemorrhage
|
0.00%
0/4 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/13 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/14 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/4 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
8.3%
1/12 • Number of events 1 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/7 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/7 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/8 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/6 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/34 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
|
Blood and lymphatic system disorders
Lymphopenia
|
—
0/0 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/13 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/14 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
—
0/0 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
—
0/0 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
—
0/0 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
—
0/0 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
—
0/0 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/6 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
2.9%
1/34 • Number of events 1 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
|
Cardiac disorders
Cardiomyopathy
|
—
0/0 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/13 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
7.1%
1/14 • Number of events 1 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
—
0/0 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
—
0/0 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
—
0/0 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
—
0/0 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
—
0/0 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/6 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/34 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
|
Cardiac disorders
Palpitations
|
—
0/0 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
7.7%
1/13 • Number of events 1 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/14 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
—
0/0 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
—
0/0 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
—
0/0 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
—
0/0 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
—
0/0 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/6 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/34 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
|
Cardiac disorders
Pericardial effusion
|
—
0/0 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
7.7%
1/13 • Number of events 1 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/14 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
—
0/0 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
—
0/0 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
—
0/0 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
—
0/0 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
—
0/0 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/6 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/34 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
|
Cardiac disorders
Supraventricular tachycardia
|
—
0/0 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/13 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/14 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
—
0/0 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
—
0/0 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
—
0/0 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
—
0/0 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
—
0/0 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/6 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
2.9%
1/34 • Number of events 1 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
|
Endocrine disorders
Adrenal insufficiency
|
—
0/0 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/13 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
7.1%
1/14 • Number of events 1 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
—
0/0 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
—
0/0 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
—
0/0 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
—
0/0 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
—
0/0 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/6 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
2.9%
1/34 • Number of events 1 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
|
Endocrine disorders
Hypothyroidism
|
—
0/0 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/13 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/14 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
—
0/0 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
—
0/0 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
—
0/0 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
—
0/0 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
—
0/0 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/6 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
2.9%
1/34 • Number of events 1 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
|
Eye disorders
Ocular hyperaemia
|
—
0/0 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/13 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
7.1%
1/14 • Number of events 1 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
—
0/0 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
—
0/0 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
—
0/0 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
—
0/0 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
—
0/0 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/6 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/34 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
|
Eye disorders
Optic nerve disorder
|
—
0/0 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/13 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/14 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
—
0/0 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
—
0/0 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
—
0/0 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
—
0/0 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
—
0/0 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/6 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
2.9%
1/34 • Number of events 1 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
|
Eye disorders
Photophobia
|
—
0/0 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/13 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/14 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
—
0/0 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
—
0/0 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
—
0/0 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
—
0/0 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
—
0/0 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/6 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
2.9%
1/34 • Number of events 1 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
|
Eye disorders
Uveitis
|
—
0/0 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/13 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
7.1%
1/14 • Number of events 1 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
—
0/0 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
—
0/0 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
—
0/0 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
—
0/0 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
—
0/0 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/6 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/34 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
|
Gastrointestinal disorders
Abdominal pain upper
|
—
0/0 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/13 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/14 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
—
0/0 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
—
0/0 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
—
0/0 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
—
0/0 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
—
0/0 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/6 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
5.9%
2/34 • Number of events 3 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
|
Gastrointestinal disorders
Abdominal pain lower
|
—
0/0 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/13 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
7.1%
1/14 • Number of events 1 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
—
0/0 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
—
0/0 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
—
0/0 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
—
0/0 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
—
0/0 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/6 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/34 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
|
Gastrointestinal disorders
Dyspepsia
|
—
0/0 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
7.7%
1/13 • Number of events 1 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/14 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
—
0/0 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
—
0/0 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
—
0/0 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
—
0/0 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
—
0/0 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/6 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/34 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
|
Gastrointestinal disorders
Dysphagia
|
—
0/0 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/13 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/14 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
—
0/0 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
—
0/0 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
—
0/0 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
—
0/0 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
—
0/0 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/6 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
2.9%
1/34 • Number of events 1 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
|
Gastrointestinal disorders
Hypoaesthesia oral
|
—
0/0 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/13 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/14 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
—
0/0 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
—
0/0 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
—
0/0 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
—
0/0 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
—
0/0 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/6 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
2.9%
1/34 • Number of events 1 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
|
Gastrointestinal disorders
Oral pain
|
—
0/0 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
7.7%
1/13 • Number of events 1 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/14 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
—
0/0 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
—
0/0 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
—
0/0 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
—
0/0 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
—
0/0 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/6 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/34 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
|
Gastrointestinal disorders
Retching
|
—
0/0 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/13 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/14 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
—
0/0 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
—
0/0 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
—
0/0 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
—
0/0 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
—
0/0 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/6 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
2.9%
1/34 • Number of events 1 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
|
Gastrointestinal disorders
Small intestinal obstruction
|
—
0/0 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/13 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/14 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
—
0/0 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
—
0/0 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
—
0/0 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
—
0/0 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
—
0/0 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/6 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
2.9%
1/34 • Number of events 1 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
|
Gastrointestinal disorders
Tongue ulceration
|
—
0/0 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/13 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/14 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
—
0/0 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
—
0/0 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
—
0/0 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
—
0/0 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
—
0/0 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/6 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
2.9%
1/34 • Number of events 1 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
|
General disorders
Chills
|
—
0/0 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/13 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/14 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
—
0/0 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
—
0/0 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
—
0/0 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
—
0/0 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
—
0/0 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/6 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
5.9%
2/34 • Number of events 2 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
|
General disorders
Asthenia
|
—
0/0 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/13 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/14 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
—
0/0 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
—
0/0 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
—
0/0 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
—
0/0 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
—
0/0 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/6 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
2.9%
1/34 • Number of events 1 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
|
General disorders
Chest discomfort
|
—
0/0 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/13 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/14 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
—
0/0 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
—
0/0 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
—
0/0 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
—
0/0 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
—
0/0 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/6 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
2.9%
1/34 • Number of events 1 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
|
General disorders
Disease progression
|
—
0/0 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
7.7%
1/13 • Number of events 1 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/14 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
—
0/0 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
—
0/0 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
—
0/0 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
—
0/0 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
—
0/0 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/6 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/34 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
|
General disorders
Early satiety
|
—
0/0 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/13 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/14 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
—
0/0 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
—
0/0 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
—
0/0 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
—
0/0 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
—
0/0 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/6 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
2.9%
1/34 • Number of events 1 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
|
General disorders
Gait disturbance
|
—
0/0 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/13 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
7.1%
1/14 • Number of events 1 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
—
0/0 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
—
0/0 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
—
0/0 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
—
0/0 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
—
0/0 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/6 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/34 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
|
General disorders
Generalised oedema
|
—
0/0 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/13 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/14 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
—
0/0 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
—
0/0 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
—
0/0 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
—
0/0 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
—
0/0 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
16.7%
1/6 • Number of events 1 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/34 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
|
General disorders
Oedema
|
—
0/0 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/13 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/14 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
—
0/0 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
—
0/0 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
—
0/0 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
—
0/0 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
—
0/0 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/6 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
2.9%
1/34 • Number of events 1 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
|
Hepatobiliary disorders
Hepatotoxicity
|
—
0/0 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
7.7%
1/13 • Number of events 2 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
7.1%
1/14 • Number of events 1 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
—
0/0 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
—
0/0 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
—
0/0 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
—
0/0 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
—
0/0 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/6 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/34 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
|
Hepatobiliary disorders
Hepatic function abnormal
|
—
0/0 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/13 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/14 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
—
0/0 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
—
0/0 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
—
0/0 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
—
0/0 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
—
0/0 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/6 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
2.9%
1/34 • Number of events 1 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
|
Hepatobiliary disorders
Jaundice
|
—
0/0 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
7.7%
1/13 • Number of events 1 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/14 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
—
0/0 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
—
0/0 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
—
0/0 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
—
0/0 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
—
0/0 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/6 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/34 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
|
Immune system disorders
Drug hypersensitivity
|
—
0/0 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/13 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/14 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
—
0/0 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
—
0/0 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
—
0/0 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
—
0/0 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
—
0/0 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/6 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
2.9%
1/34 • Number of events 1 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
|
Infections and infestations
Candida infection
|
—
0/0 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/13 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/14 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
—
0/0 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
—
0/0 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
—
0/0 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
—
0/0 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
—
0/0 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/6 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
2.9%
1/34 • Number of events 1 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
|
Infections and infestations
Folliculitis
|
—
0/0 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/13 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/14 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
—
0/0 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
—
0/0 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
—
0/0 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
—
0/0 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
—
0/0 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
16.7%
1/6 • Number of events 1 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/34 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
|
Infections and infestations
Nail infection
|
—
0/0 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/13 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
7.1%
1/14 • Number of events 1 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
—
0/0 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
—
0/0 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
—
0/0 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
—
0/0 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
—
0/0 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/6 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/34 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
|
Infections and infestations
Oral herpes
|
—
0/0 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
7.7%
1/13 • Number of events 1 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/14 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
—
0/0 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
—
0/0 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
—
0/0 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
—
0/0 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
—
0/0 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/6 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/34 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
|
Infections and infestations
Sinusitis
|
—
0/0 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/13 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/14 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
—
0/0 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
—
0/0 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
—
0/0 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
—
0/0 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
—
0/0 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/6 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
2.9%
1/34 • Number of events 1 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
|
Infections and infestations
Tinea infection
|
—
0/0 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/13 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/14 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
—
0/0 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
—
0/0 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
—
0/0 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
—
0/0 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
—
0/0 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/6 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
2.9%
1/34 • Number of events 1 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
|
Infections and infestations
Vaginal infection
|
—
0/0 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/13 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/14 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
—
0/0 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
—
0/0 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
—
0/0 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
—
0/0 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
—
0/0 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/6 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
2.9%
1/34 • Number of events 1 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
|
Injury, poisoning and procedural complications
Contusion
|
—
0/0 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/13 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/14 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
—
0/0 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
—
0/0 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
—
0/0 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
—
0/0 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
—
0/0 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/6 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
2.9%
1/34 • Number of events 1 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
|
Injury, poisoning and procedural complications
Thermal burn
|
—
0/0 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/13 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/14 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
—
0/0 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
—
0/0 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
—
0/0 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
—
0/0 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
—
0/0 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/6 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
2.9%
1/34 • Number of events 1 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
|
Investigations
Blood pressure increased
|
—
0/0 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
7.7%
1/13 • Number of events 1 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/14 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
—
0/0 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
—
0/0 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
—
0/0 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
—
0/0 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
—
0/0 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/6 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/34 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
|
Investigations
Protein total decreased
|
—
0/0 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/13 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/14 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
—
0/0 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
—
0/0 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
—
0/0 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
—
0/0 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
—
0/0 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/6 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
2.9%
1/34 • Number of events 1 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
|
Investigations
Troponin T increased
|
—
0/0 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/13 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
7.1%
1/14 • Number of events 1 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
—
0/0 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
—
0/0 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
—
0/0 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
—
0/0 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
—
0/0 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/6 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/34 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
|
Investigations
Urine output decreased
|
—
0/0 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/13 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/14 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
—
0/0 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
—
0/0 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
—
0/0 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
—
0/0 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
—
0/0 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/6 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
2.9%
1/34 • Number of events 1 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
|
Metabolism and nutrition disorders
Hypoglycaemia
|
—
0/0 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/13 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/14 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
—
0/0 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
—
0/0 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
—
0/0 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
—
0/0 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
—
0/0 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/6 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
5.9%
2/34 • Number of events 2 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
|
Metabolism and nutrition disorders
Metabolic acidosis
|
—
0/0 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/13 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/14 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
—
0/0 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
—
0/0 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
—
0/0 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
—
0/0 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
—
0/0 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
16.7%
1/6 • Number of events 1 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
2.9%
1/34 • Number of events 1 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
|
Metabolism and nutrition disorders
Hypercalcaemia
|
—
0/0 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/13 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/14 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
—
0/0 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
—
0/0 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
—
0/0 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
—
0/0 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
—
0/0 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/6 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
2.9%
1/34 • Number of events 1 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
|
Metabolism and nutrition disorders
Hyperphosphataemia
|
—
0/0 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/13 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/14 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
—
0/0 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
—
0/0 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
—
0/0 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
—
0/0 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
—
0/0 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/6 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
2.9%
1/34 • Number of events 1 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
|
Musculoskeletal and connective tissue disorders
Arthritis
|
—
0/0 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/13 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/14 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
—
0/0 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
—
0/0 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
—
0/0 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
—
0/0 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
—
0/0 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/6 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
2.9%
1/34 • Number of events 1 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
|
Musculoskeletal and connective tissue disorders
Joint stiffness
|
—
0/0 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
7.7%
1/13 • Number of events 1 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/14 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
—
0/0 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
—
0/0 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
—
0/0 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
—
0/0 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
—
0/0 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/6 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/34 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
|
Musculoskeletal and connective tissue disorders
Joint swelling
|
—
0/0 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/13 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/14 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
—
0/0 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
—
0/0 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
—
0/0 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
—
0/0 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
—
0/0 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/6 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
2.9%
1/34 • Number of events 1 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
|
Musculoskeletal and connective tissue disorders
Musculoskeletal pain
|
—
0/0 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/13 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
7.1%
1/14 • Number of events 2 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
—
0/0 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
—
0/0 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
—
0/0 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
—
0/0 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
—
0/0 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/6 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/34 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
|
Musculoskeletal and connective tissue disorders
Musculoskeletal stiffness
|
—
0/0 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/13 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/14 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
—
0/0 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
—
0/0 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
—
0/0 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
—
0/0 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
—
0/0 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/6 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
2.9%
1/34 • Number of events 1 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
|
Musculoskeletal and connective tissue disorders
Myopathy
|
—
0/0 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/13 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/14 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
—
0/0 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
—
0/0 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
—
0/0 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
—
0/0 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
—
0/0 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/6 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
2.9%
1/34 • Number of events 1 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Tumour pain
|
—
0/0 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
7.7%
1/13 • Number of events 1 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/14 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
—
0/0 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
—
0/0 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
—
0/0 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
—
0/0 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
—
0/0 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
16.7%
1/6 • Number of events 1 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
2.9%
1/34 • Number of events 1 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Cancer pain
|
—
0/0 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/13 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/14 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
—
0/0 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
—
0/0 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
—
0/0 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
—
0/0 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
—
0/0 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/6 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
2.9%
1/34 • Number of events 1 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Osteosarcoma
|
—
0/0 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/13 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/14 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
—
0/0 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
—
0/0 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
—
0/0 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
—
0/0 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
—
0/0 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/6 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
2.9%
1/34 • Number of events 1 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
|
Nervous system disorders
Burning sensation
|
—
0/0 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/13 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/14 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
—
0/0 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
—
0/0 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
—
0/0 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
—
0/0 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
—
0/0 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/6 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
2.9%
1/34 • Number of events 1 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
|
Nervous system disorders
Dysgeusia
|
—
0/0 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/13 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
7.1%
1/14 • Number of events 1 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
—
0/0 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
—
0/0 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
—
0/0 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
—
0/0 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
—
0/0 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/6 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/34 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
|
Nervous system disorders
Neuropathy peripheral
|
—
0/0 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/13 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/14 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
—
0/0 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
—
0/0 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
—
0/0 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
—
0/0 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
—
0/0 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/6 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
2.9%
1/34 • Number of events 1 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
|
Nervous system disorders
Peripheral sensory neuropathy
|
—
0/0 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/13 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/14 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
—
0/0 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
—
0/0 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
—
0/0 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
—
0/0 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
—
0/0 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/6 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
2.9%
1/34 • Number of events 1 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
|
Nervous system disorders
Restless legs syndrome
|
—
0/0 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/13 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
7.1%
1/14 • Number of events 1 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
—
0/0 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
—
0/0 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
—
0/0 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
—
0/0 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
—
0/0 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/6 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/34 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
|
Nervous system disorders
Syncope
|
—
0/0 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/13 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/14 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
—
0/0 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
—
0/0 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
—
0/0 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
—
0/0 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
—
0/0 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/6 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
2.9%
1/34 • Number of events 1 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
|
Psychiatric disorders
Anxiety
|
—
0/0 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/13 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/14 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
—
0/0 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
—
0/0 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
—
0/0 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
—
0/0 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
—
0/0 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
33.3%
2/6 • Number of events 2 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
2.9%
1/34 • Number of events 1 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
|
Psychiatric disorders
Confusional state
|
—
0/0 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/13 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
7.1%
1/14 • Number of events 1 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
—
0/0 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
—
0/0 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
—
0/0 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
—
0/0 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
—
0/0 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/6 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
2.9%
1/34 • Number of events 1 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
|
Renal and urinary disorders
Acute kidney injury
|
—
0/0 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/13 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
7.1%
1/14 • Number of events 1 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
—
0/0 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
—
0/0 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
—
0/0 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
—
0/0 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
—
0/0 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/6 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
2.9%
1/34 • Number of events 1 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
|
Renal and urinary disorders
Haematuria
|
—
0/0 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/13 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
7.1%
1/14 • Number of events 1 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
—
0/0 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
—
0/0 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
—
0/0 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
—
0/0 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
—
0/0 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/6 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/34 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
|
Renal and urinary disorders
Renal failure
|
—
0/0 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/13 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/14 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
—
0/0 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
—
0/0 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
—
0/0 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
—
0/0 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
—
0/0 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/6 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
2.9%
1/34 • Number of events 1 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
|
Reproductive system and breast disorders
Uterine polyp
|
—
0/0 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/13 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/14 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
—
0/0 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
—
0/0 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
—
0/0 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
—
0/0 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
—
0/0 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/6 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
2.9%
1/34 • Number of events 1 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
|
Respiratory, thoracic and mediastinal disorders
Dyspnoea exertional
|
—
0/0 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/13 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
7.1%
1/14 • Number of events 1 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
—
0/0 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
—
0/0 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
—
0/0 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
—
0/0 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
—
0/0 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
16.7%
1/6 • Number of events 1 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/34 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
|
Respiratory, thoracic and mediastinal disorders
Chronic obstructive pulmonary disease
|
—
0/0 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/13 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/14 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
—
0/0 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
—
0/0 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
—
0/0 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
—
0/0 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
—
0/0 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
16.7%
1/6 • Number of events 2 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/34 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
|
Respiratory, thoracic and mediastinal disorders
Pneumonitis
|
—
0/0 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/13 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/14 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
—
0/0 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
—
0/0 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
—
0/0 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
—
0/0 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
—
0/0 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/6 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
2.9%
1/34 • Number of events 1 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
|
Respiratory, thoracic and mediastinal disorders
Pulmonary embolism
|
—
0/0 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
7.7%
1/13 • Number of events 1 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/14 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
—
0/0 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
—
0/0 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
—
0/0 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
—
0/0 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
—
0/0 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/6 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/34 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
|
Respiratory, thoracic and mediastinal disorders
Pulmonary oedema
|
—
0/0 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/13 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/14 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
—
0/0 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
—
0/0 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
—
0/0 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
—
0/0 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
—
0/0 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/6 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
2.9%
1/34 • Number of events 1 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
|
Respiratory, thoracic and mediastinal disorders
Upper-airway cough syndrome
|
—
0/0 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/13 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/14 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
—
0/0 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
—
0/0 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
—
0/0 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
—
0/0 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
—
0/0 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/6 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
2.9%
1/34 • Number of events 1 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
|
Skin and subcutaneous tissue disorders
Rash morbilliform
|
—
0/0 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/13 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/14 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
—
0/0 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
—
0/0 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
—
0/0 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
—
0/0 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
—
0/0 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/6 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
8.8%
3/34 • Number of events 4 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
|
Skin and subcutaneous tissue disorders
Blister
|
—
0/0 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/13 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/14 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
—
0/0 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
—
0/0 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
—
0/0 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
—
0/0 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
—
0/0 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/6 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
2.9%
1/34 • Number of events 1 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
|
Skin and subcutaneous tissue disorders
Hyperhidrosis
|
—
0/0 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/13 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/14 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
—
0/0 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
—
0/0 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
—
0/0 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
—
0/0 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
—
0/0 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/6 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
2.9%
1/34 • Number of events 1 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
|
Skin and subcutaneous tissue disorders
Pain of skin
|
—
0/0 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/13 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/14 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
—
0/0 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
—
0/0 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
—
0/0 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
—
0/0 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
—
0/0 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/6 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
2.9%
1/34 • Number of events 1 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
|
Skin and subcutaneous tissue disorders
Skin ulcer
|
—
0/0 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/13 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/14 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
—
0/0 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
—
0/0 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
—
0/0 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
—
0/0 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
—
0/0 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/6 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
2.9%
1/34 • Number of events 1 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
|
Skin and subcutaneous tissue disorders
Urticaria papular
|
—
0/0 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/13 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
7.1%
1/14 • Number of events 1 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
—
0/0 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
—
0/0 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
—
0/0 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
—
0/0 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
—
0/0 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/6 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/34 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
|
Surgical and medical procedures
Nephrostomy tube removal
|
—
0/0 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/13 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/14 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
—
0/0 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
—
0/0 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
—
0/0 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
—
0/0 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
—
0/0 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/6 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
2.9%
1/34 • Number of events 1 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
|
Surgical and medical procedures
Tracheostomy
|
—
0/0 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
7.7%
1/13 • Number of events 1 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/14 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
—
0/0 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
—
0/0 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
—
0/0 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
—
0/0 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
—
0/0 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/6 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/34 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
|
Vascular disorders
Deep vein thrombosis
|
—
0/0 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/13 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/14 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
—
0/0 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
—
0/0 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
—
0/0 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
—
0/0 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
—
0/0 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/6 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
2.9%
1/34 • Number of events 1 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
|
Vascular disorders
Embolism
|
—
0/0 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/13 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
7.1%
1/14 • Number of events 1 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
—
0/0 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
—
0/0 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
—
0/0 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
—
0/0 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
—
0/0 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/6 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
0.00%
0/34 • Adverse events were collected from the first dose of brimarafenib through 30 days after the last dose of brimarafenib or initiation of new anticancer therapy, whichever occurred first. The maximum treatment duration was 47 months. All-cause mortality was assessed from study start through study completion (Approximately 5.5 years)
|
Additional Information
Results disclosure agreements
- Principal investigator is a sponsor employee Mapkure has 18 months from the end of the study at all sites to publish overall study results. After the 1st multi-site publication or the expiration of publication period, Investigators are free to publish/present the results of the study. Investigators must submit all draft publications/presentations to us for review 60 days prior to the planned publication/presentation date. Mapkure may request deletion of its confidential information \& may request a further delay to protect its IP rights.
- Publication restrictions are in place
Restriction type: OTHER